var title_f4_4_4160="Interdigital scabies";
var content_f4_4_4160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interdigital lesions of scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The essential lesion is a small, erythematous, nondescript papule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4160=[""].join("\n");
var outline_f4_4_4160=null;
var title_f4_4_4161="RA wrist osteopenia x-ray";
var content_f4_4_4161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of osteopenia of the wrist in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal radiograph of the left wrist in the AP projection (A) is compared with the left wrist of a patient with rheumatoid arthritis (B). The subtle diffuse osteopenia of the carpal bones is typified by an overall decrease in the density of the bones and by a relative paucity of trabecular markings. Less subtle is the prominent soft tissue nodule overlying the styloid process (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image B courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4161=[""].join("\n");
var outline_f4_4_4161=null;
var title_f4_4_4162="Normal anagen hair and loose anagen syndrome hair";
var content_f4_4_4162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal anagen hair and loose anagen syndrome hair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 205px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal anagen hairs have pigmented, distorted bulbs and an attached root sheath (left). Hairs shed from the scalp in patients with loose anagen syndrome have a ruffled cuticle and lack an attached root sheath (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolff K, Goldsmith LA, Katz S, et al. Fitzpatrick's Dermatology in General Medicine, 7th ed, McGraw-Hill Professional 2008. Copyright &copy; 2008 The McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4162=[""].join("\n");
var outline_f4_4_4162=null;
var title_f4_4_4163="Sodium lactate: Patient drug information";
var content_f4_4_4163=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium lactate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/21/8530?source=see_link\">",
"     see \"Sodium lactate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691886",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high acid levels in the blood.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702940",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium lactate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11311 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4163=[""].join("\n");
var outline_f4_4_4163=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013230\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013229\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013233\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013234\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013236\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013232\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013237\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013238\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/21/8530?source=related_link\">",
"      Sodium lactate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_4_4164="Tegaserod: Drug information";
var content_f4_4_4164=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tegaserod: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zelnorm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zelnorm&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F224927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Serotonin 5-HT",
"      <sub>",
"       4",
"      </sub>",
"      Receptor Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F224909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      IBS with constipation:",
"     </b>",
"     Females &lt;55 years of age: Oral: 6 mg twice daily, before meals, for 4-6 weeks; may consider continuing treatment for an additional 4-6 weeks in patients who respond initially",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic idiopathic constipation:",
"     </b>",
"     Females &lt;55 years of age: Oral: 6 mg twice daily, before meals; the need for continued therapy should be reassessed periodically",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F224910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in elderly women (&ge;55 years of age) is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F224911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC of the inactive metabolite are increased with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F224912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC of tegaserod are increased with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild impairment: No dosage adjustment recommended; however, use caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate-to-severe impairment: Use is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F224884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zelnorm&reg;: 2 mg, 6 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F224873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Available in U.S. under an emergency investigational new drug (IND) process. Emergency situations are defined as immediately life-threatening or requiring hospitalization. Physicians with patients who may qualify can contact the FDA&rsquo;s Division of Drug Information via email (druginfo@fda.hhs.gov). The FDA may either deny the request or authorize shipment of Zelnorm&reg; by Novartis. Additional information can be found at",
"     <a href=\"file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm\" target=\"_blank\">",
"      file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F224886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer 30 minutes before meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F224885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Emergency treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in women (&lt;55 years of age) in which no alternative therapy exists",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F224925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (4%), migraine (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (9%; severe &lt;1%), nausea (8%), flatulence (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (5%), arthropathy (2%), leg pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Albuminuria, alopecia, ALT increased, angina pectoris, arrhythmia, AST increased, bile duct stone, cramps, cholecystitis (with increased transaminases), gangrenous bowel, hepatitis, hypersensitivity reaction, hypokalemia (secondary to diarrhea), hypotension, ischemic colitis, mesenteric ischemia, MI, pruritus, rectal bleeding, renal pain, severe diarrhea (complicated by hypovolemia, hypotension, syncope), sphincter of Oddi spasm (suspected), stroke, syncope, tenesmus, unstable angina, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F224889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Per product labeling: Hypersensitivity to tegaserod or any component of the formulation; severe renal impairment; moderate or severe hepatic impairment; history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions. Treatment should not be started in patients with diarrhea or in those who experience diarrhea frequently.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Exclusion criteria under the emergency-IND process: Unstable angina, history of MI or stroke, hypertension, hyperlipidemia, diabetes, age &ge;55 years, smoking, obesity, depression, anxiety, or suicidal ideation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F224876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse reactions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Serious cardiovascular events (eg, MI, stroke, unstable angina) may occur; patients should seek emergency care following any sign and symptom suggestive of a serious cardiac event.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: May occur after the start of treatment, most cases reported as a single episode within the first week of therapy, and may resolve with continued dosing. However, serious consequences of diarrhea (hypovolemia, syncope) have been reported; patients should be warned to contact healthcare provider immediately if they develop severe diarrhea, or diarrhea with severe cramping, abdominal pain, or dizziness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intestinal ischemic events: Use has been associated with rare intestinal ischemic events; discontinue immediately with new or sudden worsening abdominal pain or rectal bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use will not be permitted in patients with unstable angina, a history of MI or stroke, hyperlipidemia, cigarette smoking, hypertension, or obesity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use will not be permitted in patients with depression or anxiety, or with any signs of suicidal ideation or behavior.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use will not be permitted in patients with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild hepatic impairment; not recommended with moderate or severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly women: Contraindicated in women &ge;55 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Males: Safety and efficacy have not been established in males.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risk vs benefit: Potential benefits should be weighed against potential risks in qualifying patients eligible for emergency-IND use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F224903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Bioavailability is decreased by 40% to 65% and C",
"     <sub>",
"      max",
"     </sub>",
"     is decreased by 20% to 40% when taken with food. T",
"     <sub>",
"      max",
"     </sub>",
"     is prolonged from 1 hour up to 2 hours when taken following a meal, but decreased to 0.7 hours when taken 30 minutes before a meal. Management: Take on an empty stomach 30 minutes before meals.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F224881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F224892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy have not been established in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F224915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F224893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach, 30 minutes before meals.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F224894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Colonaid (CN, PY);",
"     </li>",
"     <li>",
"      Coloserod (UY);",
"     </li>",
"     <li>",
"      Gasprid (CO);",
"     </li>",
"     <li>",
"      Prozerada (DO, GT, HN, NI);",
"     </li>",
"     <li>",
"      Tegibs (IN);",
"     </li>",
"     <li>",
"      Zelmac (AR, AU, BR, CH, CL, CZ, EC, HK, ID, IL, KP, MX, MY, NZ, PE, PK, SG, TH, TW, VE);",
"     </li>",
"     <li>",
"      Zelnorm (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F224875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tegaserod is a partial neuronal 5-HT",
"     <sub>",
"      4",
"     </sub>",
"     receptor agonist. Its action at the receptor site leads to stimulation of the peristaltic reflex and intestinal secretion, and moderation of visceral sensitivity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F224888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 368 &plusmn; 223 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98% primarily to &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: GI: Hydrolysis in the stomach; Hepatic: Oxidation, conjugation, and glucuronidation; metabolite (negligible activity); significant first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Fasting: 10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: 11 &plusmn; 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~66% as unchanged drug); urine (~33% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10200 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-42B5A9483A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4164=[""].join("\n");
var outline_f4_4_4164=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224906\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224907\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224927\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224909\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224910\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224911\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224912\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224884\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224873\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234337\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224886\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224885\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224925\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224889\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224876\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300106\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223182\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224903\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224881\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224892\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224915\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224893\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224894\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224875\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224888\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10200\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10200|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_4_4165="Exogenous hyperthyroidism";
var content_f4_4_4165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exogenous hyperthyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4165/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4165/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4165/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4165/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4165/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4165/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/4/4165/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous hyperthyroidism is the term used to describe hyperthyroidism caused by ingestion of excessive amounts of thyroid hormone. It may be intentional (ie, suppressive doses of thyroxine to treat thyroid cancer) or inadvertent (ie, contamination of dietary supplements). When exogenous hyperthyroidism is due to the surreptitious ingestion of thyroid hormone, it is termed thyrotoxicosis factitia.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of exogenous hyperthyroidism will be reviewed here. An overview of disorders that cause hyperthyroidism is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous hyperthyroidism is caused by the ingestion of excessive amounts of thyroid hormone.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     Levothyroxine",
"    </a>",
"    is the most widely used thyroid hormone preparation, but the hormone is also available as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/51/1846?source=see_link\">",
"     liothyronine",
"    </a>",
"    (T3, Cytomel),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/39/9846?source=see_link\">",
"     thyroid extract (desiccated thyroid)",
"    </a>",
"    , and mixtures of synthetic T4 and T3 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38917?source=see_link\">",
"     liotrix",
"    </a>",
"    , Thyrolar). Symptoms from exogenous hyperthyroidism frequently occur at doses in excess of 200 mcg for thyroxine, 50 mcg for liothyronine, 120 mg for desiccated thyroid, and 37.5 mcg",
"    <span class=\"nowrap\">",
"     T3/150",
"    </span>",
"    mcg T4 for Thyrolar. However, most patients are taking considerably higher doses.",
"   </p>",
"   <p>",
"    Exogenous hyperthyroidism can occur in several clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/1\">",
"     1",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with thyroid cancer prescribed suppressive doses of thyroxine to minimize potential TSH stimulation of tumor growth.",
"     </li>",
"     <li>",
"      Patients with goiter prescribed excessive doses in an attempt to shrink the thyroid gland.",
"     </li>",
"     <li>",
"      Patients with a psychiatric disorder who may intentionally take excessive doses of thyroid hormone.",
"     </li>",
"     <li>",
"      Other patients, with or without the help of a clinician, may take excessive doses to treat obesity, menstrual disorders, depression, or infertility.",
"     </li>",
"     <li>",
"      Patients who intentionally or accidentally (particularly children) take an overdose of thyroid hormone. Accidental overdose has also been described in adults taking weight-reducing dietary supplements (purchased over the internet) that claimed to contain only herbs, but also contained significant amounts of both T3 and T4 or animal thyroid tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A novel form of exogenous hyperthyroidism is the ingestion of thyroid tissue inadvertently removed and ground up with neck muscle in slaughterhouses to prepare hamburger; this has resulted in at least two community outbreaks of thyrotoxicosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The terms hamburger thyroiditis and hamburger hyperthyroidism were applied to these outbreaks because the clinical presentation mimicked that of painless thyroiditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=see_link\">",
"     \"Painless thyroiditis\"",
"    </a>",
"    .) Patients who ate large quantities of \"thyroid burgers\" became thyrotoxic for several weeks to months until their freezers were depleted, after which they had transient hypothyroidism. Subsequent case reports have described similar findings after ingestion of beef or sausage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5374728\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and signs in patients who take excessive doses of thyroid hormone are similar to those in patients with hyperthyroidism from other causes, such as Graves' disease. The classic symptoms include weight loss, heat intolerance, tremor, palpitations, anxiety, increased frequency of bowel movements, and shortness of breath. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, two important exceptions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exophthalmos (ophthalmopathy) occurs only in patients with Graves' hyperthyroidism because it is not caused by thyroid hormone per se. However, lid lag and lid retraction, signs of catecholamine excess, do occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"       \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is usually no goiter because exogenous thyroid hormone in amounts sufficient to cause hyperthyroidism inhibits thyrotropin (TSH) secretion, resulting in thyroid atrophy. In patients with goiter given thyroid hormone in an attempt to reduce goiter size, however, the goiter may persist despite exogenous hyperthyroidism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute thyroxine overdose can cause acute hyperthyroidism. Myocardial infarction also can occur, especially in elderly patients, and seizures have rarely been described in children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In most cases, however, particularly in children (who ingested a parent's medication), accidental ingestion of many milligrams of thyroxine and the accompanying transient marked elevation in serum thyroxine (T4) concentrations cause few symptoms and signs of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic thyroxine overdose can cause chronic overt (low serum TSH, high free T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T3) or subclinical (low serum TSH with normal free T4) hyperthyroidism. The skeleton and the cardiovascular system are the major target tissues adversely affected by chronic overt and subclinical hyperthyroidism, although abnormalities in other systems have been reported (",
"    <a class=\"graphic graphic_table graphicRef79602 \" href=\"UTD.htm?37/20/38219\">",
"     table 1",
"    </a>",
"    ). Overt hyperthyroidism is most clearly associated with accelerated bone remodeling, reduced bone density, osteoporosis, and an increase in fracture rate, especially in postmenopausal women. In some but not all studies, even subclinical hyperthyroidism is also associated with low bone density in postmenopausal women. In addition, the frequency of atrial fibrillation is increased in older patients with subclinical hyperthyroidism, as it is in patients with overt hyperthyroidism. These topics are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link&amp;anchor=H6#H6\">",
"     \"Subclinical hyperthyroidism\", section on 'Clinical findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=see_link&amp;anchor=H9#H9\">",
"     \"Bone disease with hyperthyroidism and thyroid hormone therapy\", section on 'Subclinical hyperthyroidism due to exogenous thyroid hormone therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=see_link&amp;anchor=H6#H6\">",
"     \"Cardiovascular effects of hyperthyroidism\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5374735\">",
"    <span class=\"h2\">",
"     Laboratory and imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with exogenous hyperthyroidism have low serum TSH concentrations. Serum thyroxine (T4)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    triiodothyronine (T3) may be elevated or normal, depending upon the degree of hyperthyroidism and which thyroid hormone preparation was ingested. Serum thyroglobulin is suppressed and 24-hour radioiodine uptake is low due to suppression of TSH secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of exogenous hyperthyroidism is based upon the clinical manifestations, laboratory findings, and 24-hour radioiodine uptake. Patients with exogenous hyperthyroidism have classic biochemical findings (low TSH, elevated or normal free T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T3). The absence of goiter, a low serum thyroglobulin concentration, and a low or undetectable 24-hour radioiodine uptake differentiate exogenous hyperthyroidism from other causes of hyperthyroidism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 24-hour radioiodine uptake in the thyroid is less than 1 percent in patients with exogenous hyperthyroidism due to the suppression of TSH secretion, except in patients with some autonomously functioning thyroid tissue. In addition to exogenous hyperthyroidism, other causes of hyperthyroidism with low 24-hour radioiodine uptake values include any of the different types of thyroiditis associated with release of preformed hormone from an inflamed gland, and sometimes iodine-induced hyperthyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=see_link\">",
"       \"Overview of thyroiditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum thyroglobulin concentrations are low in patients with exogenous hyperthyroidism in the absence of goiter or thyroid cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/12\">",
"       12",
"      </a>",
"      ]. In contrast, they are high in hyperthyroid patients with endogenous hyperthyroidism, including functional metastatic thyroid cancer, struma ovarii, thyroiditis, and iodine-induced hyperthyroidism. Whenever serum thyroglobulin is measured, a test for antithyroglobulin antibodies should be performed at the same time (good laboratories do the latter first) because serum thyroglobulin measurements are unreliable if antithyroglobulin antibodies are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the setting of thyroid cancer or goiter, intentional intake of exogenous thyroid hormone is easily identified. In addition, a careful history may reveal intentional intake of excessive doses of thyroid hormone to treat psychiatric disorders or accidental ingestion of thyroid hormone (diet pills, contaminated meat). Surreptitious use of thyroid hormone is usually more difficult to detect.",
"   </p>",
"   <p>",
"    The serum concentrations of T4 and T3 may be useful in identifying the type of thyroid hormone ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, patients taking excessive amounts of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/51/1846?source=see_link\">",
"     liothyronine",
"    </a>",
"    have high serum T3 and low serum T4 concentrations. Those taking thyroxine have high serum T4 and T3 concentrations, but the",
"    <span class=\"nowrap\">",
"     T4/T3",
"    </span>",
"    ratio is higher than that in most patients with spontaneously occurring hyperthyroidism. Conversely, patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/39/9846?source=see_link\">",
"     thyroid extract",
"    </a>",
"    or Thyrolar have higher than normal serum",
"    <span class=\"nowrap\">",
"     T3/T4",
"    </span>",
"    ratios, like most patients with Graves' hyperthyroidism, toxic nodules, and toxic nodular goiter. The latter two preparations contain relatively more T3 than T4.",
"   </p>",
"   <p>",
"    Fecal T4 measurements have been suggested as a method for diagnosing surreptitious exogenous hyperthyroidism. In one study, fecal T4 values were approximately 0.8",
"    <span class=\"nowrap\">",
"     mcg/g",
"    </span>",
"    (1",
"    <span class=\"nowrap\">",
"     nmol/g)",
"    </span>",
"    in normal subjects and were increased twofold in patients with Graves' hyperthyroidism and 12- to 24-fold in patients with exogenous hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuation or reduction in the dose of thyroid hormone is usually the only treatment needed. When therapy is stopped in patients taking thyroxine, serum T4 concentrations fall about 50 percent in seven days. T3 is cleared more rapidly (serum half-life about one day). However, very symptomatic patients may benefit from additional therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta-adrenergic antagonist drugs will relieve many of the symptoms of hyperthyroidism promptly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"       \"Beta blockers in the treatment of hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients taking thyroxine (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/39/9846?source=see_link\">",
"       thyroid extract",
"      </a>",
"      ), the radiographic contrast agents ipodate or iopanoic acid can be given to inhibit T4 conversion to T3 (these drugs are presently not available in the United States) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/1\">",
"       1",
"      </a>",
"      ]. The usual dose is 500 mg once daily; treatment is rarely needed for longer than seven days. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=see_link\">",
"       \"Iodinated radiocontrast agents in the treatment of hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       Cholestyramine",
"      </a>",
"      can be given to bind T4 and T3 in the intestine, thereby interrupting the normal enterohepatic circulation of the two hormones [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/14\">",
"       14",
"      </a>",
"      ]. The usual dose is 4 g four times a day.",
"     </li>",
"     <li>",
"      Patients (usually children) seen shortly after accidental ingestion of very large doses of thyroid hormone may be treated by induced emesis, gastric lavage, and intragastric instillation of charcoal.",
"     </li>",
"     <li>",
"      While plasmapheresis and exchange transfusion have been used to treat massive thyroid hormone overdose [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/1\">",
"       1",
"      </a>",
"      ], most patients, especially children, have few symptoms and signs of hyperthyroidism and conservative management is usually satisfactory [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4165/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9769345\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exogenous hyperthyroidism is the term used to describe hyperthyroidism caused by ingestion of excessive amounts of thyroid hormone. It may be intentional or inadvertent. It can occur in several clinical settings, including ingestion of excessive doses to treat thyroid cancer or to shrink the thyroid gland in patients with goiter, or through ingestion of weight-reducing dietary supplements containing T4, T3, or animal thyroid tissue. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms and signs in patients who take excessive doses of thyroid hormone are similar to those in patients with hyperthyroidism from other causes and include weight loss, heat intolerance, tremor, palpitations, anxiety, increased frequency of bowel movements, and shortness of breath. Unless underlying thyroid disease is present, there is no goiter or ophthalmopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"       \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of exogenous hyperthyroidism is based upon clinical manifestations (presence of hyperthyroid symptoms, absence of goiter), abnormal thyroid function tests (low TSH, elevated or normal free T4",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      T3), a low serum thyroglobulin concentration, and a low or undetectable 24-hour radioiodine uptake. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discontinuation or reduction in the dose of thyroid hormone is usually the only treatment needed for most patients. When therapy is stopped in patients taking thyroxine, serum T4 concentrations fall about 50 percent in seven days. T3 is cleared more rapidly (serum half-life about one day). Beta-adrenergic antagonist drugs can be used briefly to immediately relieve many of the symptoms of hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/1\">",
"      Cohen JH 3rd, Ingbar SH, Braverman LE. Thyrotoxicosis due to ingestion of excess thyroid hormone. Endocr Rev 1989; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/2\">",
"      Ohye H, Fukata S, Kanoh M, et al. Thyrotoxicosis caused by weight-reducing herbal medicines. Arch Intern Med 2005; 165:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/3\">",
"      Ioos V, Das V, Maury E, et al. A thyrotoxicosis outbreak due to dietary pills in Paris. Ther Clin Risk Manag 2008; 4:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/4\">",
"      Poon WT, Ng SW, Lai CK, et al. Factitious thyrotoxicosis and herbal dietary supplement for weight reduction. Clin Toxicol (Phila) 2008; 46:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/5\">",
"      Hedberg CW, Fishbein DB, Janssen RS, et al. An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med 1987; 316:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/6\">",
"      Kinney JS, Hurwitz ES, Fishbein DB, et al. Community outbreak of thyrotoxicosis: epidemiology, immunogenetic characteristics, and long-term outcome. Am J Med 1988; 84:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/7\">",
"      Hendriks LE, Looij BJ. Hyperthyroidism caused by excessive consumption of sausages. Neth J Med 2010; 68:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/8\">",
"      Parmar MS, Sturge C. Recurrent hamburger thyrotoxicosis. CMAJ 2003; 169:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/9\">",
"      Shammas NW, Richeson JF, Pomerantz R. Myocardial dysfunction and necrosis after ingestion of thyroid hormone. Am Heart J 1994; 127:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/10\">",
"      Locker GJ, Kotzmann H, Frey B, et al. Factitious hyperthyroidism causing acute myocardial infarction. Thyroid 1995; 5:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/11\">",
"      Gorman RL, Chamberlain JM, Rose SR, Oderda GM. Massive levothyroxine overdose: high anxiety--low toxicity. Pediatrics 1988; 82:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/12\">",
"      Mariotti S, Martino E, Cupini C, et al. Low serum thyroglobulin as a clue to the diagnosis of thyrotoxicosis factitia. N Engl J Med 1982; 307:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/13\">",
"      Bouillon R, Verresen L, Staels F, et al. The measurement of fecal thyroxine in the diagnosis of thyrotoxicosis factitia. Thyroid 1993; 3:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4165/abstract/14\">",
"      Shakir KM, Michaels RD, Hays JH, Potter BB. The use of bile acid sequestrants to lower serum thyroid hormones in iatrogenic hyperthyroidism. Ann Intern Med 1993; 118:112.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7840 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-BAD001EFC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4165=[""].join("\n");
var outline_f4_4_4165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9769345\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5374728\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5374735\">",
"      Laboratory and imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9769345\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7840\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7840|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/20/38219\" title=\"table 1\">",
"      Clinical manifestations subclinical hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=related_link\">",
"      Beta blockers in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=related_link\">",
"      Bone disease with hyperthyroidism and thyroid hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=related_link\">",
"      Iodinated radiocontrast agents in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=related_link\">",
"      Overview of thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=related_link\">",
"      Painless thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=related_link\">",
"      Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_4_4166="Adenomatoid malform CXR III";
var content_f4_4_4166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52148%7EPULM%2F79904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52148%7EPULM%2F79904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic adenomatoid malformation of the left lower lobe in 30-year-old man with recurrent pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A frontal chest radiograph shows a mass-like consolidation involving primarily the superior segment of the left lower lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic adenomatoid malformation of the left lower lobe in 30-year-old man with recurrent pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan displays the multicystic nature of the mass-like consolidation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4166=[""].join("\n");
var outline_f4_4_4166=null;
var title_f4_4_4167="The role of platelets in coronary heart disease";
var content_f4_4_4167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The role of platelets in coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4167/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4167/contributors\">",
"     Jane E Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4167/contributors\">",
"     Joseph Loscalzo, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4167/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4167/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4167/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4167/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/4/4167/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets play an important role in cardiovascular disease both in the pathogenesis of atherosclerosis and in the development of acute thrombotic events. Their importance in coronary disease and in acute coronary syndromes is indirectly confirmed by the benefit of antiplatelet agents (particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and the glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors) in these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PLATELET ADHESION AND AGGREGATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both superficial and deep intimal injury disrupt the intact endothelium, which normally prevents the adherence of platelets by the production of the antiplatelet agents nitric oxide and prostacyclin. Disruption of the endothelium also exposes collagen. These factors lead to the adherence of platelets to the subendothelium, both directly and via von Willebrand factor, and, subsequently, to platelet activation (",
"    <a class=\"graphic graphic_figure graphicRef57152 \" href=\"UTD.htm?22/40/23170\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63712 \" href=\"UTD.htm?21/45/22239\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is a brief summary of platelet adhesion and aggregation. These processes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=see_link\">",
"     \"Platelet biology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adhesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet adhesion is mediated by the binding of platelet receptors to a number of arterial wall receptors, including subendothelial collagen (whose corresponding platelet receptor is Gp",
"    <span class=\"nowrap\">",
"     Ia/IIa),",
"    </span>",
"    von Willebrand factor (Gp",
"    <span class=\"nowrap\">",
"     Ib/IX",
"    </span>",
"    and Gp",
"    <span class=\"nowrap\">",
"     IIb/III),",
"    </span>",
"    and fibrinogen (Gp",
"    <span class=\"nowrap\">",
"     IIb/IIIa).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Binding",
"    of platelets to these structural proteins in concert with the action of soluble receptor-mediated stimulants, such as thrombin, adenosine diphosphate (ADP), and thromboxane A2 (TxA2), induces platelet activation. This process involves the mobilization of calcium from intracellular stores, the activation of several intracellular kinases, and the release of arachidonic acid from membrane phospholipids, resulting in the generation of TxA2 (",
"    <a class=\"graphic graphic_figure graphicRef70151 \" href=\"UTD.htm?11/41/11925\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/2\">",
"     2",
"    </a>",
"    ]. Platelet activation produced in vivo is enhanced by circulating catecholamines [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Aggregation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet aggregation results from conversion of the",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor to a form that can bind adhesive proteins, such as fibrinogen. This process is normally opposed by the secretion of nitric oxide and of prostacyclin (PGI2), another product of arachidonic acid metabolism, from the vascular endothelium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;During and after aggregation, platelets release many substances that can induce further platelet accumulation and activation, vasoconstriction, thrombosis, and mitogenesis, including ADP, serotonin, platelet-derived growth factor, fibroblast growth factor, ADP, serotonin, platelet factor 4, and &szlig;-thromboglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Platelet-released serotonin normally causes vasodilation; however, it can induce vasoconstriction in the presence of damaged or abnormal (dysfunctional) endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activated platelets also release nitric oxide&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This response may prevent an excessive response by inhibiting platelet recruitment to the growing thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF THE ACUTE ISCHEMIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiographic severity of coronary stenosis does not adequately predict the location of subsequent coronary artery occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, rupture of atheromatous plaque and subsequent occlusive thrombus formation are believed to be responsible for most acute myocardial ischemic events, such as unstable angina and acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. However, systemic effects, such as inflammation, are more widespread within the coronary circulation and lead to instability of multiple plaques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Interaction of thrombosis and inflammation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coronary thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery thrombosis is the final pathogenic mechanism of acute ischemic events, including myocardial infarction and sudden cardiac arrest. There are complex interactions among the atherosclerotic artery, endothelial injury and dysfunction, vasospasm, and platelet activation. Plaque rupture exposes thrombogenic subendothelial components, leading to platelet deposition and activation.",
"   </p>",
"   <p>",
"    The following observations are compatible with the importance of platelet thrombus formation in acute ischemic syndromes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombus formation within a coronary vessel is the acute precipitating event in most unstable ischemic coronary syndromes, as documented by angiographic and pathologic studies [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Among patients with sudden death due to coronary thrombosis, the thrombi typically have a layered appearance indicative of episodic growth [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/14\">",
"       14",
"      </a>",
"      ]. Episodic growth may alternate with intermittent fragmentation of the thrombus, leading to distal embolization of both thrombus and platelet aggregates and microinfarction [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=see_link\">",
"       \"Pathology and pathogenesis of the vulnerable plaque\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aggregating platelets form the core of the growing thrombotic mass (white thrombus) at the disrupted plaque; the associated reduction in blood flow promotes upstream",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      downstream propagation of fibrin and red blood cell and leukocyte rich red thrombus [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Both subendothelial tissue factor and activated platelets themselves serve as stimuli for thrombin generation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. Platelets provide a membrane surface for the assembly of procoagulants, two of which (factors V and VIII) are released with activation. Persistent thrombotic occlusion of the coronary vessel leads to acute myocardial infarction.",
"     </li>",
"     <li>",
"      Increased platelet-derived thromboxane A2 and other prothrombotic prostaglandin metabolites have been found in patients with acute myocardial infarction and unstable angina, providing biochemical support for platelet activation as the cause of these events [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/14,21\">",
"       14,21",
"      </a>",
"      ]. One prospective study, for example, found a phasic increase in the excretion of thromboxane A2 metabolites in 84 percent of episodes of unstable angina [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with unstable angina have elevated levels of P-selectin, an integral membrane protein involved in platelet adhesion [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/22\">",
"       22",
"      </a>",
"      ]. Pulsatile shear stress, as occurs in stenotic arteries, can cause platelet aggregation via an increased expression of P-selectin [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/23\">",
"       23",
"      </a>",
"      ]. Hydrodynamic shear stress, resulting from plaque rupture, can activate platelets and cause both platelet aggregation (via glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      and von Willebrand factor) and platelet-mediated neutrophil aggregation via upregulation of P-selectin [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"       \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Although levels of P-selectin decrease during the first month after treatment, levels remain higher than normal even with therapy with glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitors, suggesting continued platelet activation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/25\">",
"       25",
"      </a>",
"      ]. This finding is consistent with serial angioscopic studies showing persistence of complex yellow plaque and thrombus after successful reperfusion at one month and later [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"       \"The role of the vulnerable plaque in acute coronary syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aggregating platelets from patients with acute coronary syndromes produce less nitric oxide than those from patients with stable or no angina [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/27\">",
"       27",
"      </a>",
"      ]. Why this might occur is not known, but impaired nitric oxide production can enhance platelet aggregation and thrombus formation.",
"     </li>",
"     <li>",
"      Despite treatment with platelet inhibitors, patients with acute cardiovascular events have enhanced platelet reactivity even at baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are consistent with another platelet-related factor that has been associated with cardiovascular thrombosis, which is the presence of larger, more reactive platelets in patients with acute ischemic events [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The increase in platelet size, which is in compensation for a persistent decrease in platelet count, results from the ongoing consumption of platelets in unstable angina; this is not seen in an acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, platelets from patients with unstable angina, as determined by studying platelet aggregability ex vivo, are hyperaggregable [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/33\">",
"     33",
"    </a>",
"    ]. These effects promote thrombus growth, limitation of blood flow, and acute ischemia.",
"   </p>",
"   <p>",
"    Platelet reactivity is altered by a number of environmental factors, such as age, serum cholesterol, diabetes, catecholamine levels, cigarette smoking, and alcohol consumption. However, data from the Framingham Heart Study suggest that these factors play only a minor role, accounting for only 4 to 7 percent of variance; in contrast, estimates suggest that heritable factors play a major role, accounting for 20 to 30 percent of the overall variance in platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Polymorphisms of platelet glycoprotein receptor genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The functions of the platelet glycoprotein receptors have been described above. It has been suggested that polymorphisms in these receptors are a risk factor for coronary artery thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/35\">",
"     35",
"    </a>",
"    ], although data from Framingham suggest that these polymorphisms contribute minimally to platelet function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/34\">",
"     34",
"    </a>",
"    ]. Associations have been described for Gp IIIa polymorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/36\">",
"     36",
"    </a>",
"    ] and Gp",
"    <span class=\"nowrap\">",
"     Ia/IIa",
"    </span>",
"    polymorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, many of these findings have not been confirmed in larger studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/34,39\">",
"     34,39",
"    </a>",
"    ] or meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Interaction of thrombosis and inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of most platelet inhibitors is inhibition of fibrinogen-dependent platelet-platelet association.",
"   </p>",
"   <p>",
"    Platelets are also involved in the inflammatory response and produce proinflammatory mediators such as platelet-derived growth factor, platelet factor 4, and transforming growth factor-beta, as well as CD40 ligand. Patients with acute coronary syndromes have increased interactions between platelets (homotypic aggregates) and between platelets and",
"    <span class=\"nowrap\">",
"     leukocytes/neutrophils",
"    </span>",
"    (heterotypic aggregates). These latter aggregates form when platelets are activated and adhere to circulating leukocytes or neutrophils.",
"   </p>",
"   <p>",
"    Accumulating information suggests that inflammation plays an important role during the thrombotic phase of acute coronary syndromes. Leukocytes and neutrophils bind to platelets via P-selectin and beta-2-integrin, a process that requires platelet production of platelet-activating factor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. Leukocytes in turn may be able to enhance platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], and the relationship between platelet-dependent thrombosis and inflammation is also governed, in part, by the platelet-surface receptor CD40 and its binding of CD40 ligand. These interactions suggest a mechanism for the coupling of thrombosis and inflammation during cardiac ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POSSIBLE ROLE OF PLATELETS IN ATHEROSCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for platelets in the evolutionary phase of the atherosclerotic plaque is suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelets adhere to exposed subendothelium after endothelial injury and release vasoactive substances that induce smooth muscle cell migration and proliferation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/48,49\">",
"       48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Platelets may serve as a lipid source in the development of the fatty streak [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Platelets can promote foam cell formation even in the absence of hyperlipidemia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there is no direct clinical evidence that platelets contribute to coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Possible role in stable coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets may play a role in stable coronary artery disease. This hypothesis is supported by a study in which circulating degranulated or activated platelets, enhanced platelet reactivity, and an increase in circulating monocyte-platelet aggregates were demonstrated in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4167/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101460356\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelets are activated by sequential steps, including adhesion, platelet-platelet interaction, and recruitment, which leads to thrombus formation.",
"     </li>",
"     <li>",
"      Coronary artery thrombosis is the final pathogenic mechanism of acute ischemic events, including myocardial infarction and sudden cardiac arrest. There are complex interactions within the atherosclerotic artery, endothelial injury and dysfunction, vasospasm, and platelet activation. Plaque rupture exposes thrombogenic subendothelial components, leading to platelet deposition and activation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathogenesis of the acute ischemic syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Platelets may also have a role in the evolutionary phase of the atherosclerotic plaque. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Possible role of platelets in atherosclerosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/1\">",
"      Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359:938.",
"     </a>",
"    </li>",
"    <li>",
"     Ware, JA, Coller, BS. Platelet morphology, biochemistry and function. In: Williams' Hematology, Beutler, E, Lichtman, MA, Coller, BS, Kipps, TJ (Eds), McGraw Hill, New York 1994. p.1161.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/3\">",
"      Lauri D, Cerletti C, de Gaetano G. Amplification of primary response of human platelets to platelet-activating factor: aspirin-sensitive and aspirin-insensitive pathways. J Lab Clin Med 1985; 105:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/4\">",
"      Stein B, Fuster V, Israel DH, et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 1989; 14:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/5\">",
"      McFadden EP, Clarke JG, Davies GJ, et al. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991; 324:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/6\">",
"      Chen LY, Mehta JL. Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets. J Cardiovasc Pharmacol 1996; 27:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/7\">",
"      Freedman JE, Loscalzo J, Barnard MR, et al. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/8\">",
"      Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/9\">",
"      Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/10\">",
"      Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/11\">",
"      Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/12\">",
"      MacIsaac AI, Thomas JD, Topol EJ. Toward the quiescent coronary plaque. J Am Coll Cardiol 1993; 22:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/13\">",
"      DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/14\">",
"      Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/15\">",
"      Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/16\">",
"      Ueda Y, Asakura M, Hirayama A, et al. Intracoronary morphology of culprit lesions after reperfusion in acute myocardial infarction: serial angioscopic observations. J Am Coll Cardiol 1996; 27:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/17\">",
"      Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/18\">",
"      Moreno PR, Bernardi VH, L&oacute;pez-Cu&eacute;llar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94:3090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/19\">",
"      Ardissino D, Merlini PA, Ari&euml;ns R, et al. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/20\">",
"      Santos MT, Valles J, Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest 1991; 87:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/21\">",
"      Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/22\">",
"      Ikeda H, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation 1995; 92:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/23\">",
"      Merten M, Chow T, Hellums JD, Thiagarajan P. A new role for P-selectin in shear-induced platelet aggregation. Circulation 2000; 102:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/24\">",
"      Konstantopoulos K, Neelamegham S, Burns AR, et al. Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and beta2-integrin. Circulation 1998; 98:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/25\">",
"      Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999; 33:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/26\">",
"      Ueda Y, Asakura M, Yamaguchi O, et al. The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up. J Am Coll Cardiol 2001; 38:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/27\">",
"      Freedman JE, Ting B, Hankin B, et al. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 1998; 98:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/28\">",
"      Frelinger AL 3rd, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113:2888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/29\">",
"      Erusalimsky JD, Martin JF. The regulation of megakaryocyte polyploidization and its implications for coronary artery occlusion. Eur J Clin Invest 1993; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/30\">",
"      Brown AS, Hong Y, de Belder A, et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/31\">",
"      Endler G, Klimesch A, Sunder-Plassmann H, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/32\">",
"      Mathur A, Robinson MS, Cotton J, et al. Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb Haemost 2001; 85:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/33\">",
"      Grande P, Grauholt AM, Madsen JK. Unstable angina pectoris. Platelet behavior and prognosis in progressive angina and intermediate coronary syndrome. Circulation 1990; 81:I16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/34\">",
"      O'Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001; 103:3051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/35\">",
"      Simmonds RE, Hermida J, Rezende SM, Lane DA. Haemostatic genetic risk factors in arterial thrombosis. Thromb Haemost 2001; 86:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/36\">",
"      Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bbeta 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997; 96:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/37\">",
"      Moshfegh K, Wuillemin WA, Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999; 353:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/38\">",
"      Casorelli I, De Stefano V, Leone AM, et al. The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. Br J Haematol 2001; 114:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/39\">",
"      Marian AJ, Brugada R, Kleiman NS. Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction. N Engl J Med 1996; 335:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/40\">",
"      Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. Am J Cardiol 2000; 86:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/41\">",
"      Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis. Thromb Haemost 2001; 85:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/42\">",
"      Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood 1997; 89:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/43\">",
"      Ostrovsky L, King AJ, Bond S, et al. A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process. Blood 1998; 91:3028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/44\">",
"      Li N, Hu H, Lindqvist M, et al. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/45\">",
"      Hu H, Varon D, Hjemdahl P, et al. Platelet-leukocyte aggregation under shear stress: differential involvement of selectins and integrins. Thromb Haemost 2003; 90:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/46\">",
"      Faraday N, Scharpf RB, Dodd-o JM, et al. Leukocytes can enhance platelet-mediated aggregation and thromboxane release via interaction of P-selectin glycoprotein ligand 1 with P-selectin. Anesthesiology 2001; 94:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/47\">",
"      Del Maschio A, Evangelista V, Rajtar G, et al. Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents. Am J Physiol 1990; 258:H870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/48\">",
"      Hoak JC. Platelets and atherosclerosis. Semin Thromb Hemost 1988; 14:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/49\">",
"      Dav&igrave; G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/50\">",
"      CHANDLER AB, HAND RA. Phagocytized platelets: a source of lipids in human thrombi and atherosclerotic plaques. Science 1961; 134:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/51\">",
"      Mendelsohn ME, Loscalzo J. Role of platelets in cholesteryl ester formation by U-937 cells. J Clin Invest 1988; 81:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/52\">",
"      Elwood PC, Renaud S, Beswick AD, et al. Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort. Heart 1998; 80:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4167/abstract/53\">",
"      Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31:352.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1498 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-D201336892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4167=[""].join("\n");
var outline_f4_4_4167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H101460356\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PLATELET ADHESION AND AGGREGATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adhesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Aggregation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS OF THE ACUTE ISCHEMIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coronary thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Polymorphisms of platelet glycoprotein receptor genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Interaction of thrombosis and inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POSSIBLE ROLE OF PLATELETS IN ATHEROSCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Possible role in stable coronary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101460356\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1498\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1498|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/40/23170\" title=\"figure 1\">",
"      Pathways of platelet activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/45/22239\" title=\"figure 2\">",
"      Mechanisms of platelet activation with vascular injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/41/11925\" title=\"figure 3\">",
"      Mechanism platelet activation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=related_link\">",
"      Pathology and pathogenesis of the vulnerable plaque",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_4_4168="Overview of kidney disease in HIV-infected patients";
var content_f4_4_4168=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of kidney disease in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4168/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4168/contributors\">",
"     Christina M Wyatt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4168/contributors\">",
"     Paul E Klotman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4168/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4168/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4168/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4168/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/4/4168/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H31719887\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;With dramatic improvements in survival and disease progression in the era of highly active antiretroviral therapy (HAART), complications such as kidney, liver, and cardiac disease have largely replaced opportunistic infections as the leading causes of mortality in the setting of HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with HIV are at risk for both acute kidney injury (AKI) and chronic kidney disease (CKD) secondary to medication nephrotoxicity, HIV-associated nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/2-5\">",
"     2-5",
"    </a>",
"    ], immune complex kidney diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/5-9\">",
"     5-9",
"    </a>",
"    ], and kidney disease in the setting of thrombotic microangiopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In addition, the aging cohort of HIV-infected patients may be at increased risk for kidney disease related to hepatitis B or C virus coinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/5,12,13\">",
"     5,12,13",
"    </a>",
"    ] and comorbid or treatment-related diabetes and hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31719894\">",
"    <span class=\"h1\">",
"     ACUTE KIDNEY INJURY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15534502\">",
"    <span class=\"h2\">",
"     Epidemiology of AKI in HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the introduction of highly active antiretroviral therapy (HAART), acute kidney injury (AKI) was commonly attributed to septicemia, volume depletion, or medication toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15534676\">",
"    <span class=\"h3\">",
"     Incidence of AKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of AKI in HIV-infected patients is higher than it is in patients without HIV. The incidence of AKI in patients with HIV has also increased over time. This was documented in a study of hospitalized adults in New York state which compared administrative data from 1995 (before the introduction of HAART) to data from 2003 (after the introduction of HAART) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/16\">",
"     16",
"    </a>",
"    ]. Compared with non-infected hospitalized patients, AKI was documented in a significantly greater proportion of HIV-infected hospitalized patients, both in 1995 (2.9 versus 1 percent) and 2003 (6 versus 2.7 percent). Among HIV-infected patients, the proportion with documented AKI was two-fold higher in 2003, although in-hospital mortality was lower.",
"   </p>",
"   <p>",
"    In a prospective study of 754 ambulatory HIV-infected patients followed at a single center, at least one episode of AKI occurred in 71 patients (9.4 percent) during a two-year period (2000 to 2002, after the introduction of HAART) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15534695\">",
"    <span class=\"h3\">",
"     Risk factors for AKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some risk factors for AKI among HIV-infected patients are similar to risk factors for AKI in the general population, such as older age, diabetes mellitus, preexisting chronic kidney disease (CKD), and acute or chronic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/16\">",
"     16",
"    </a>",
"    ]. However, some risk factors are specific to HIV. In the study of 754 HIV-infected patients mentioned above, for example, AKI occurred more frequently among those receiving HAART (12 versus 4 percent) and those with an AIDS-defining illness (30 versus 7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/17\">",
"     17",
"    </a>",
"    ]. Other predictors of AKI included a low CD4 count, a high viral load, and coinfection with hepatitis C, which is common in patients with HIV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15534728\">",
"    <span class=\"h3\">",
"     Outcomes after AKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to the general population, the development of AKI increases the risk of death in patients with HIV. The following examples illustrate an association with both short-term and long-term outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inpatient mortality was significantly more frequent among HIV-infected patients who had AKI than among HIV-infected patients without AKI in a 2003 sample of hospitalized patients in New York state (27 versus 4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Long-term mortality is also higher among HIV-infected individuals who develop AKI. In a national sample of US military veterans from 1986 through 2006, 17,325 HIV-infected patients were hospitalized and survived for at least 90 days after discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/18\">",
"       18",
"      </a>",
"      ]. AKI occurred in 3060 (18 percent); 334 of these patients with AKI also required dialysis. During an average follow-up of 5.7 years after hospital discharge, the HIV-infected patients who experienced AKI were significantly more likely to die (56 versus 47 percent). End-stage renal disease (ESRD) and cardiovascular events were also more common among HIV-infected patients with AKI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15534510\">",
"    <span class=\"h2\">",
"     Causes of AKI in HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common types of AKI in patients with HIV infection, similar to patients without HIV, are prerenal states and acute tubular necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best data come from a prospective study of 754 HIV-infected patients followed at a single center; 111 episodes of AKI developed in 71 patients during a two-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/17\">",
"     17",
"    </a>",
"    ]. The major types of AKI in this population included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prerenal states, including true volume depletion, heart failure, and cirrhosis (39 percent)",
"     </li>",
"     <li>",
"      Acute tubular necrosis, including ischemic and nephrotoxic (37 percent)",
"     </li>",
"     <li>",
"      Crystalluria with obstruction (5 percent)",
"     </li>",
"     <li>",
"      Interstitial nephritis (5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31719901\">",
"    <span class=\"h3\">",
"     Medication nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HIV infection are at risk for nephrotoxicity from HAART, as well as from medications used to treat opportunistic infections or hepatitis virus coinfection. In addition, HAART-treated patients are often taking additional medications for the treatment of comorbid conditions or HAART-related complications. Medication nephrotoxicity may present with acute or chronic kidney injury or with acid-base and electrolyte disturbances. (See",
"    <a class=\"local\" href=\"#H31719915\">",
"     'Chronic kidney disease'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15534424\">",
"     'Electrolyte disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some of the more commonly implicated agents include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protease inhibitors &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       Indinavir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      are protease inhibitors that can cause crystalluria and AKI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link&amp;anchor=H4164392#H4164392\">",
"       \"Crystal-induced acute kidney injury (acute renal failure)\", section on 'Protease inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      &ndash; Tenofovir is a nucleoside reverse transcriptase inhibitor that can cause AKI with or without proximal tubular dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=see_link&amp;anchor=H14340801#H14340801\">",
"       \"Pharmacology of nucleoside reverse transcriptase inhibitors\", section on 'Tenofovir'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other antiviral agents &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      are drugs used to treat herpes simplex virus or cytomegalovirus infection. Each of these agents can be associated with the development of AKI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link&amp;anchor=H101518418#H101518418\">",
"       \"Crystal-induced acute kidney injury (acute renal failure)\", section on 'Acyclovir'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link&amp;anchor=H7#H7\">",
"       \"Foscarnet: An overview\", section on 'Renal insufficiency'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=see_link&amp;anchor=H6#H6\">",
"       \"Cidofovir: An overview\", section on 'Toxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anti-Pneumocystis drugs &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      and, less commonly,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      are agents used to treat Pneumocystis infection. Trimethoprim-sulfamethoxazole can produce interstitial nephritis, while approximately 25 percent of patients treated with pentamidine develop reversible AKI that is likely due to nephrotoxic acute tubular necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/18-21\">",
"       18-21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of acute interstitial nephritis\", section on 'Drugs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H966867\">",
"    <span class=\"h3\">",
"     HIV-associated thrombotic microangiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-associated thrombotic microangiopathy can present with significant AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The etiology is unknown. As an example, studies in pigtailed macaques infected with HIV-2 failed to demonstrate a direct role for HIV infection of kidney epithelial or endothelial cells in thrombotic microangiopathy involving the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Results of a large observational cohort study suggest that systemic thrombotic microangiopathy is a rare complication of HIV infection in the HAART era [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/24\">",
"     24",
"    </a>",
"    ]. HIV-associated thrombotic microangiopathy can result in CKD in some patients due to incomplete recovery from the acute injury. (See",
"    <a class=\"local\" href=\"#H15534526\">",
"     'Causes of CKD in HIV-infected patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31719915\">",
"    <span class=\"h1\">",
"     CHRONIC KIDNEY DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15534518\">",
"    <span class=\"h2\">",
"     Epidemiology of CKD in HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence and incidence of HIV-related end-stage renal disease (ESRD) are projected to increase as the prevalence of HIV infection continues to rise [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, the prevalence of chronic kidney disease (CKD) associated with HIV infection varies according to the population studied; the following examples illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort of 2059 HIV-infected women followed in the Women's Interagency HIV Study (WIHS) both before and after the introduction of highly active antiretroviral therapy (HAART), nearly one-third of 2059 subjects had persistent proteinuria at enrollment, and two percent of the cohort developed clinically significant renal failure over five years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/20\">",
"       20",
"      </a>",
"      ]. Advanced HIV infection was associated with both baseline proteinuria and the development of acute or chronic kidney disease in this cohort. In addition, hepatitis C coinfection and elevated baseline creatinine were associated with the development of kidney disease.",
"     </li>",
"     <li>",
"      In a prospective cohort of 22,156 HIV-infected military veterans followed for eight years, 27 patients (0.1 percent) had proteinuria greater than 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      at baseline, and 51 patients (0.2 percent) had an estimated glomerular filtration rate (GFR) less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      at baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/25\">",
"       25",
"      </a>",
"      ]. ESRD developed in 366 patients (1.7 percent). Patients who developed ESRD were more likely to have hypertension, diabetes, cardiovascular disease, hepatitis C coinfection, a low CD4 T cell count, and a high HIV viral load.",
"     </li>",
"     <li>",
"      In a cross-sectional analysis of 783 HIV-infected men in the prospective Multicenter AIDS Cohort Study (MACS), 5 to 7 percent had an estimated GFR less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , depending upon the method used to estimate GFR [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/26\">",
"       26",
"      </a>",
"      ]. The prevalence of decreased estimated GFR was higher among older patients and among those with hepatitis C coinfection or a higher HIV viral load.",
"     </li>",
"     <li>",
"      In a cross-sectional study of 300 HIV-infected patients from the East African Republic of Burundi, 46 percent were diagnosed with CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/27\">",
"       27",
"      </a>",
"      ]. However, only two percent had an estimated GFR less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , while the remainder had persistent urinary abnormalities (principally persistent pyuria).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15534526\">",
"    <span class=\"h2\">",
"     Causes of CKD in HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of CKD in patients with HIV ranges from HIV-independent disorders (such as hypertension, diabetes, and incomplete recovery from an episode of acute kidney injury [AKI]) to HIV-related disorders (such as HIV-associated nephropathy [HIVAN]). Glomerular diseases which may occur more commonly in HIV-infected patients than in the general population include HIVAN, immune complex mediated glomerulonephritis, and glomerulonephritis secondary to hepatitis C virus coinfection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31719922\">",
"    <span class=\"h3\">",
"     HIV-associated nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic kidney disease of HIV infection, HIV-associated nephropathy (HIVAN), was first described in 1984 in patients with advanced HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIVAN is a collapsing form of focal sclerosing glomerulosclerosis (FSGS) with associated tubular microcysts and interstitial inflammation. HIVAN classically presents with significant proteinuria and rapidly progressive kidney disease in the setting of normal blood pressure and normal to enlarged kidneys, although the presentation may be less dramatic in the HAART era. The pathogenesis, clinical manifestations, diagnosis, and treatment of HIVAN are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31719929\">",
"    <span class=\"h3\">",
"     Immune complex mediated glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly 40 percent of HIV-infected patients with proteinuric kidney disease and suspected HIVAN will have an alternative diagnosis on biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/5\">",
"     5",
"    </a>",
"    ]. A number of immune complex kidney diseases have been reported in patients with HIV infection, including membranous nephropathy, membranoproliferative and mesangial proliferative glomerulonephritis, and \"lupus-like\" proliferative glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Though rare, IgA nephropathy has also been reported in the setting of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, a unique immune complex kidney disease with a characteristic \"ball in cup\" basement membrane reaction was first described in a South African biopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/28\">",
"     28",
"    </a>",
"    ]. Although this disease is often referred to as HIV immune complex kidney disease (HIVICK), the pathogenic relationship between HIV infection and the development of HIVICK and other immune complex kidney diseases has not been extensively studied, and the role of viral antigens in circulating immune complexes and deposits has been debated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/7,29\">",
"     7,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history and response of immune complex kidney disease to HAART have not been well described, although existing data suggest that the course of HIV-associated immune complex disease may be similar to that in uninfected patients. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small series of four patients with HIV-associated IgA nephropathy, for example, the kidney disease followed a benign course similar to that observed in the absence of HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective cohort including 42 patients with biopsy-proven HIVAN and 47 patients with alternative renal diagnoses, patients with non-HIVAN kidney disease had less advanced HIV infection and were less likely to be black. In addition, there was no evidence of a beneficial role for HAART in non-HIVAN kidney diseases, which were associated with slower progression to ESRD regardless of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small retrospective study suggests a more aggressive course in patients with immune complex kidney disease resembling lupus glomerulonephritis. In this cohort, 10 of 14 patients progressed to ESRD within one year. Unlike other HIV-associated immune complex diseases, the \"lupus-like\" HIV-related immune complex kidney disease may be associated with black race [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31719936\">",
"    <span class=\"h3\">",
"     Glomerulonephritis due to hepatitis C virus coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus coinfection has been associated with the development of acute and chronic kidney disease in large cohort studies of HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/16,17,20\">",
"     16,17,20",
"    </a>",
"    ]. However, the histologic patterns of renal disease have not been studied in large populations of coinfected patients. Membranoproliferative glomerulonephritis (MPGN) is strongly associated with hepatitis C virus infection in the general population and is a common alternative diagnosis in coinfected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. The classic clinical findings of cryoglobulinemia and hypocomplementemia may be less common in coinfected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of hepatitis C virus associated MPGN in the setting of HIV coinfection has not been rigorously studied and may include plasmapheresis, corticosteroids, or antiviral therapy for hepatitis C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31719950\">",
"    <span class=\"h2\">",
"     Diagnosis and management of chronic kidney disease in patients with HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with expert guidelines that recommend screening and early identification of CKD in patients with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/32\">",
"     32",
"    </a>",
"    ]. All HIV-positive patients should be screened for proteinuria and reduced kidney function. Glomerular filtration rate (GFR) should be estimated using a creatinine-based estimate. CKD is identified by the presence of proteinuria or by an estimated glomerular filtration rate less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"     <sup>",
"     </sup>",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=see_link\">",
"     \"Definition and staging of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Identification of CKD in a patient with HIV should prompt nephrology referral, initiation of HAART, and tight control of comorbid diabetes and hypertension (if present). Medication doses should be adjusted for the level of glomerular filtration rate, with particular attention to nucleoside and nucleotide reverse transcriptase inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=see_link\">",
"     \"Pharmacology of nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CKD should have at least biannual monitoring of estimated GFR, with medication dose adjustments as needed. The frequency of monitoring should be increased in patients with mildly reduced GFR (ie, less than 90",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ) who are taking medications that have potential nephrotoxic effects, including the nucleotide analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and boosted protease inhibitor therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early referral to a nephrologist is important to coordinate diagnosis and treatment of CKD in patients with HIV, including discussion of the need for dialysis and the timely placement of dialysis access in patients with progressive disease. Analyses of data from the US Renal Data System (USRDS) have demonstrated similar outcomes in HIV-positive ESRD patients treated with hemodialysis or peritoneal dialysis, as well as significant improvements in survival in the HAART era. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34344?source=see_link\">",
"     \"Human immunodeficiency virus and dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Kidney transplantation may be a safe alternative in patients with preserved immune function and undetectable viral load. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=see_link\">",
"     \"Solid organ transplantation in HIV-infected individuals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15534424\">",
"    <span class=\"h1\">",
"     ELECTROLYTE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the pre-highly active antiretroviral therapy (HAART) era, hyponatremia was the most common electrolyte disorder in patients with HIV infection. Volume depletion is the most common cause of hyponatremia in hospitalized patients regardless of HIV status, but the syndrome of inappropriate antidiuretic hormone secretion (SIADH) or adrenal insufficiency have also been implicated in some cases of HIV-related hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39332?source=see_link&amp;anchor=H2#H2\">",
"     \"Electrolyte disturbances with HIV infection\", section on 'Hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of adrenal insufficiency in the HAART era is not known, but early reports suggest that AIDS-related adrenal insufficiency was only rarely associated with clinically significant hyponatremia or hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperkalemia is more commonly associated with treatment or prophylaxis of Pneumocystis infections with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39332?source=see_link&amp;anchor=H6#H6\">",
"     \"Electrolyte disturbances with HIV infection\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with underlying chronic kidney disease (CKD) may be at increased risk for hyperkalemia, and caution should be used when combining these medications with nonsteroidal anti-inflammatory agents or inhibitors of the renin-angiotensin-aldosterone system.",
"   </p>",
"   <p>",
"    Electrolyte depletion due to tubular dysfunction has been associated with a number of agents used for the treatment of HIV and related infections, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , amphotericin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4168/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Hypophosphatemia, hypomagnesemia, and hypocalcemia can be severe and symptomatic and may require discontinuation of therapy and aggressive electrolyte repletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=see_link&amp;anchor=H14340801#H14340801\">",
"     \"Pharmacology of nucleoside reverse transcriptase inhibitors\", section on 'Tenofovir'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link&amp;anchor=H8#H8\">",
"     \"Foscarnet: An overview\", section on 'Electrolyte abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=see_link\">",
"     \"Diagnosis and treatment of hypophosphatemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=see_link\">",
"     \"Evaluation and treatment of hypomagnesemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link\">",
"     \"Treatment of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15534534\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with HIV are at risk for both acute kidney injury (AKI) and chronic kidney disease (CKD) secondary to medication nephrotoxicity, HIV-associated nephropathy, immune complex kidney diseases, and kidney disease in the setting of thrombotic microangiopathy. In addition, the aging cohort of HIV-infected patients may be at increased risk for kidney disease related to hepatitis B or C virus coinfection and comorbid or treatment-related diabetes and hypertension. (See",
"      <a class=\"local\" href=\"#H31719887\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of AKI in HIV-infected patients is higher than it is in patients without HIV. Some risk factors for AKI among HIV-infected patients are similar to risk factors for AKI in the general population, such as older age, diabetes mellitus, preexisting CKD, and acute or chronic liver disease. However, some risk factors are specific to HIV. Similar to the general population, the development of AKI increases the risk of death in patients with HIV. (See",
"      <a class=\"local\" href=\"#H15534502\">",
"       'Epidemiology of AKI in HIV-infected patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common types of AKI in HIV-infected patients are prerenal states and acute tubular necrosis, although other etiologies may also occur. (See",
"      <a class=\"local\" href=\"#H15534510\">",
"       'Causes of AKI in HIV-infected patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with HIV infection are at risk for nephrotoxicity from highly active antiretroviral therapy (HAART), as well as from medications used to treat opportunistic infections or hepatitis virus coinfection. Some of the more commonly implicated agents include the following (see",
"      <a class=\"local\" href=\"#H31719901\">",
"       'Medication nephrotoxicity'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Protease inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      , which can cause crystalluria and AKI",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      , a nucleoside reverse transcriptase inhibitor, which can cause AKI with or without proximal tubular dysfunction",
"     </li>",
"     <li>",
"      The antiviral agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      , can be associated with the development of AKI.",
"     </li>",
"     <li>",
"      Anti-Pneumocystis drugs, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      can cause AKI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence and incidence of HIV-related CKD and end-stage renal disease (ESRD) are projected to increase as the prevalence of HIV infection continues to rise. The etiology of CKD in patients with HIV ranges from HIV-independent disorders (such as hypertension, diabetes, and incomplete recovery from an episode of AKI) to HIV-related disorders (such as HIV-associated nephropathy [HIVAN]). Glomerular diseases which may occur more commonly in HIV-infected patients than in the general population include HIVAN, immune complex mediated glomerulonephritis, and glomerulonephritis secondary to hepatitis C virus coinfection. (See",
"      <a class=\"local\" href=\"#H15534518\">",
"       'Epidemiology of CKD in HIV-infected patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15534526\">",
"       'Causes of CKD in HIV-infected patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All HIV-infected patients should be screened for proteinuria and reduced kidney function. Identification of CKD in a patient with HIV should prompt nephrology referral and initiation of HAART. Medication doses should be adjusted for the level of glomerular filtration rate, with particular attention to nucleoside and nucleotide reverse transcriptase inhibitors. Patients with CKD should have at least biannual monitoring of estimated glomerular filtration rate (GFR), with medication dose adjustments as needed. The frequency of monitoring should be increased in patients who are taking medications that have potential nephrotoxic effects, including the nucleotide analog,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , and boosted protease inhibitor therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H31719950\">",
"       'Diagnosis and management of chronic kidney disease in patients with HIV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of electrolyte disorders can occur in HIV-infected patients, which may be due to HIV-associated complications or medications used to treat HIV or its complications. (See",
"      <a class=\"local\" href=\"#H15534424\">",
"       'Electrolyte disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/1\">",
"      Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002; 29:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/2\">",
"      Gardenswartz MH, Lerner CW, Seligson GR, et al. Renal disease in patients with AIDS: a clinicopathologic study. Clin Nephrol 1984; 21:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/3\">",
"      Pardo V, Aldana M, Colton RM, et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/4\">",
"      Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984; 310:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/5\">",
"      D'Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998; 18:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/6\">",
"      Casanova S, Mazzucco G, Barbiano di Belgiojoso G, et al. Pattern of glomerular involvement in human immunodeficiency virus-infected patients: an Italian study. Am J Kidney Dis 1995; 26:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/7\">",
"      Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. HIV-associated immune-mediated renal disease. Kidney Int 1993; 44:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/8\">",
"      Balow JE. Nephropathy in the context of HIV infection. Kidney Int 2005; 67:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/9\">",
"      Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/10\">",
"      Boccia RV, Gelmann EP, Baker CC, et al. A hemolytic-uremic syndrome with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/11\">",
"      Bachmeyer C, Blanche P, S&eacute;r&eacute;ni D, et al. Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in HIV-infected patients. AIDS 1995; 9:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/12\">",
"      Stokes MB, Chawla H, Brody RI, et al. Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus. Am J Kidney Dis 1997; 29:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/13\">",
"      Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/14\">",
"      Peraldi MN, Maslo C, Akposso K, et al. Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients anad sixty renal biopsies. Nephrol Dial Transplant 1999; 14:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/15\">",
"      Rao TK, Friedman EA. Outcome of severe acute renal failure in patients with acquired immunodeficiency syndrome. Am J Kidney Dis 1995; 25:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/16\">",
"      Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 20:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/17\">",
"      Franceschini N, Napravnik S, Eron JJ Jr, et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005; 67:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/18\">",
"      Choi AI, Li Y, Parikh C, et al. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int 2010; 78:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/19\">",
"      Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005; 16:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/20\">",
"      Szczech LA, Gange SJ, van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/21\">",
"      Laurinavicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int 1999; 56:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/22\">",
"      Eitner F, Cui Y, Hudkins KL, et al. Thrombotic microangiopathy in the HIV-2-infected macaque. Am J Pathol 1999; 155:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/23\">",
"      Segerer S, Eitner F, Cui Y, et al. Cellular injury associated with renal thrombotic microangiopathy in human immunodeficiency virus-infected macaques. J Am Soc Nephrol 2002; 13:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/24\">",
"      Becker S, Fusco G, Fusco J, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 2004; 39 Suppl 5:S267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/25\">",
"      Jotwani V, Li Y, Grunfeld C, et al. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am J Kidney Dis 2012; 59:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/26\">",
"      Estrella MM, Parekh RS, Astor BC, et al. Chronic kidney disease and estimates of kidney function in HIV infection: a cross-sectional study in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2011; 57:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/27\">",
"      Cailhol J, Nkurunziza B, Izzedine H, et al. Prevalence of chronic kidney disease among people living with HIV/AIDS in Burundi: a cross-sectional study. BMC Nephrol 2011; 12:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/28\">",
"      Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a South African perspective. Kidney Int 2006; 69:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/29\">",
"      Katz A, Bargman JM, Miller DC, et al. IgA nephritis in HIV-positive patients: a new HIV-associated nephropathy? Clin Nephrol 1992; 38:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/30\">",
"      Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/31\">",
"      Cheng JT, Anderson HL Jr, Markowitz GS, et al. Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. J Am Soc Nephrol 1999; 10:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/32\">",
"      Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/33\">",
"      Pi&eacute;drola G, Casado JL, L&oacute;pez E, et al. Clinical features of adrenal insufficiency in patients with acquired immunodeficiency syndrome. Clin Endocrinol (Oxf) 1996; 45:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/34\">",
"      Shah GM, Alvarado P, Kirschenbaum MA. Symptomatic hypocalcemia and hypomagnesemia with renal magnesium wasting associated with pentamidine therapy in a patient with AIDS. Am J Med 1990; 89:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4168/abstract/35\">",
"      Gradon JD, Fricchione L, Sepkowitz D. Severe hypomagnesemia associated with pentamidine therapy. Rev Infect Dis 1991; 13:511.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14027 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-0B08567BAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4168=[""].join("\n");
var outline_f4_4_4168=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15534534\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31719887\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31719894\">",
"      ACUTE KIDNEY INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15534502\">",
"      Epidemiology of AKI in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15534676\">",
"      - Incidence of AKI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15534695\">",
"      - Risk factors for AKI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15534728\">",
"      - Outcomes after AKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15534510\">",
"      Causes of AKI in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31719901\">",
"      - Medication nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H966867\">",
"      - HIV-associated thrombotic microangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31719915\">",
"      CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15534518\">",
"      Epidemiology of CKD in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15534526\">",
"      Causes of CKD in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31719922\">",
"      - HIV-associated nephropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31719929\">",
"      - Immune complex mediated glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31719936\">",
"      - Glomerulonephritis due to hepatitis C virus coinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31719950\">",
"      Diagnosis and management of chronic kidney disease in patients with HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15534424\">",
"      ELECTROLYTE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15534534\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=related_link\">",
"      Cidofovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=related_link\">",
"      Definition and staging of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=related_link\">",
"      Diagnosis and treatment of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39332?source=related_link\">",
"      Electrolyte disturbances with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=related_link\">",
"      Evaluation and treatment of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2104?source=related_link\">",
"      HIV-associated nephropathy (HIVAN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34344?source=related_link\">",
"      Human immunodeficiency virus and dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=related_link\">",
"      Pharmacology of nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=related_link\">",
"      Solid organ transplantation in HIV-infected individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=related_link\">",
"      Treatment of the mixed cryoglobulinemia syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_4_4169="Hypertension: Who should be treated?";
var content_f4_4_4169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypertension: Who should be treated?",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4169/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4169/contributors\">",
"     Johannes FE Mann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4169/contributors\">",
"     Karl F Hilgers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4169/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4169/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4169/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4169/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/4/4169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hypertension generally begins with nonpharmacologic therapy, including moderate dietary sodium restriction, weight reduction in the obese, avoidance of excess alcohol intake, and regular aerobic exercise (",
"    <a class=\"graphic graphic_table graphicRef62129 \" href=\"UTD.htm?42/24/43403\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/1\">",
"     1",
"    </a>",
"    ]. Institution of these modalities involves little or no risk and they all may be beneficial from a general health viewpoint even in normotensive subjects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link\">",
"     \"Diet in the treatment and prevention of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug therapy, in comparison, may be expensive and is often associated with side effects, some of which (hypokalemia and hyperlipidemia) may actually increase coronary risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H27627359#H27627359\">",
"     \"Causes of hypokalemia\", section on 'Diuretics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44659?source=see_link\">",
"     \"Antihypertensive drugs and lipids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, there should be clear evidence of likely benefit before antihypertensive drugs are begun. Such evidence is now available for most degrees of hypertension (systolic pressure &ge;140 mmHg and especially for diastolic pressure persistently &ge;90 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/2\">",
"     2",
"    </a>",
"    ]. There are also controversial data suggesting that treatment of prehypertension may lower the risk of developing sustained hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44677?source=see_link&amp;anchor=H8#H8\">",
"     \"Prehypertension\", section on 'Preventive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evidence that treating different degrees of hypertension is beneficial will be reviewed here, with recommendations for who should be treated. An overview of the treatment of hypertension, the choice of antihypertensive drug as initial therapy, and goal blood pressure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of hypertension in adults\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major societies have published definitions of hypertension. In general, hypertension was defined as a blood pressure",
"    <span class=\"nowrap\">",
"     &ge;140/&ge;90",
"    </span>",
"    mmHg. However, subsequent trials have identified groups of patients at higher risk in whom goal blood pressures below this value may be associated with improved outcomes. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Goal blood pressure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following definitions were suggested in 2003 by the seventh Joint National Committee (JNC 7) based upon the average of two or more properly measured readings at each of",
"    <strong>",
"     two or more visits after an initial screen",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal blood pressure: systolic &lt;120 mmHg and diastolic &lt;80 mmHg",
"     </li>",
"     <li>",
"      Prehypertension: systolic 120 to 139 mmHg or diastolic 80 to 89 mmHg",
"     </li>",
"     <li>",
"      Hypertension:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp;Stage 1: systolic 140 to 159 mmHg or diastolic 90 to 99 mmHg",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp;Stage 2: systolic &ge;160 mmHg or diastolic &ge;100 mmHg",
"   </p>",
"   <p>",
"    Isolated systolic hypertension is considered to be present when the blood pressure is",
"    <span class=\"nowrap\">",
"     &ge;140/&lt;90",
"    </span>",
"    mmHg and isolated diastolic hypertension is considered to be present when the blood pressure is",
"    <span class=\"nowrap\">",
"     &lt;140/&ge;90",
"    </span>",
"    mmHg.",
"   </p>",
"   <p>",
"    These definitions apply to adults on no antihypertensive medications and who are not acutely ill. If there is a disparity in category between the systolic and diastolic pressures, the higher value determines the severity of the hypertension. The systolic pressure is the greater predictor of risk in patients over the age of 50 to 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar but not identical definitions were suggested in the European Societies of Hypertension and Cardiology guidelines for the management of arterial hypertension that were published in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Optimal blood pressure: systolic &lt;120 mmHg and diastolic &lt;80 mmHg",
"     </li>",
"     <li>",
"      Normal: systolic 120 to 129 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic 80 to 84 mmHg",
"     </li>",
"     <li>",
"      High normal: systolic 130 to 139 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic 85 to 89 mmHg",
"     </li>",
"     <li>",
"      Hypertension:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp;Grade 1: systolic 140 to 159 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic 90 to 99 mmHg",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp;Grade 2: systolic 160 to 179 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic 100 to 109 mmHg",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp;Grade 3: systolic &ge;180",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic &ge;110 mmHg",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp;Isolated systolic hypertension: systolic &ge;140 mmHg and &lt;90 mmHg",
"   </p>",
"   <p>",
"    Both the seventh Joint National Committee (JNC 7) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/1\">",
"     1",
"    </a>",
"    ] and the European Societies of Hypertension and Cardiology (ESH-ESC) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/4\">",
"     4",
"    </a>",
"    ] guidelines provided different threshold levels to define hypertension when blood pressure was measured by 24-hour ambulatory monitoring or by home blood pressure monitoring:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      24-hour average blood pressure or the average of reading from home blood pressure monitoring &minus; Normotension is defined as a blood pressure less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg, and hypertension is defined as a blood pressure greater than or equal to",
"      <span class=\"nowrap\">",
"       135/85",
"      </span>",
"      mmHg.",
"     </li>",
"     <li>",
"      Daytime (awake) blood pressure by 24-hour ambulatory monitoring &minus; Normotension is defined as a blood pressure less than",
"      <span class=\"nowrap\">",
"       135/85",
"      </span>",
"      mmHg, and hypertension is defined as a blood pressure greater than or equal to",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg.",
"     </li>",
"     <li>",
"      Nighttime (asleep) blood pressure by 24-hour ambulatory monitoring &minus; Normotension is defined as a blood pressure less than",
"      <span class=\"nowrap\">",
"       120/70",
"      </span>",
"      mmHg, and hypertension is defined as a blood pressure greater than or equal to",
"      <span class=\"nowrap\">",
"       125/75",
"      </span>",
"      mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These definitions of hypertension using alternate measurement techniques are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link&amp;anchor=H3#H3\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Interpretation of ABPM'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link&amp;anchor=H16#H16\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Home BP measurements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WHAT LEVEL OF BP INCREASES RISK?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above definitions of hypertension were based upon studies demonstrating an increase in cardiovascular risk that could be reduced by antihypertensive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidemiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, epidemiologic studies of treated and untreated patients reveal that there is a gradually increasing incidence of coronary disease and stroke and cardiovascular mortality as the blood pressure rises above",
"    <span class=\"nowrap\">",
"     110/75",
"    </span>",
"    mmHg, with some notable differences in risk based upon age and underlying comorbid conditions (",
"    <a class=\"graphic graphic_figure graphicRef75106 graphicRef66793 \" href=\"UTD.htm?33/12/33986\">",
"     figure 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. A similar relationship has been described in patients with known coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, at any blood pressure, the cardiovascular risk is importantly affected by the presence or absence of other risk factors (",
"    <a class=\"graphic graphic_figure graphicRef55353 \" href=\"UTD.htm?24/31/25086\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/4,8\">",
"     4,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A caveat to the following discussion is that epidemiologic observations of increased risk at blood pressures above",
"    <span class=\"nowrap\">",
"     110/75",
"    </span>",
"    mmHg but below the hypertensive range do not prove causality. As an example, increasing blood pressures below the hypertensive range could be associated with other risk factors that could explain worse outcomes, such as increasing body weight and diabetes mellitus. Proof of causality can only be provided by randomized trials that show that cardiovascular outcomes are improved by lowering the blood pressure. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Decreased cardiovascular risk with therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The relative prognostic importance of different levels of blood pressure components in individuals of different ages was studied among participants in the Second National Health and Nutrition Examination Survey (NHANES II) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/6\">",
"     6",
"    </a>",
"    ]. In this cohort study of 7830 participants between the ages of 30 to 74 years who were initially free of cardiovascular disease, the baseline blood pressure was correlated with all-cause and cardiovascular mortality over a 15 year follow-up; the analysis did not take into account whether the patients were or were not treated for hypertension. Over this period, 1588 patients died, with cardiovascular disease being responsible for 582. Unlike other studies, the analysis was based upon a risk model that utilized the clear correlation between systolic and diastolic blood pressures to estimate the risk for different baseline blood pressure combinations.",
"   </p>",
"   <p>",
"    The following mortality results were obtained beyond the first two years of follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among participants less than 65 years of age, increases in the systolic blood pressure were linearly related to increases in cardiovascular and all-cause mortality at",
"      <strong>",
"       all",
"      </strong>",
"      diastolic blood pressures (",
"      <a class=\"graphic graphic_figure graphicRef62430 graphicRef57839 \" href=\"UTD.htm?29/10/29866\">",
"       figure 3A-B",
"      </a>",
"      ). By comparison, the correlation between diastolic blood pressure and mortality was \"hockey stick-shaped\". This shape corresponds to a flat region of risk with diastolic values below 80 mmHg, with a marked increase in risk occurring with values above this level.",
"     </li>",
"     <li>",
"      Among those greater than 65 years of age, increases in the systolic blood pressure were also linearly related to increased mortality at all diastolic pressures. However, the risk with the diastolic blood pressure was J-shaped; thus, for a fixed systolic pressure, decreased blood pressures below approximately 80 to 90 mmHg were associated with increasing mortality, while levels above approximately 80 to 90 mmHg were associated with an enhanced risk. Why lower diastolic pressures were associated with increased risk is not known. It is generally thought that lower pressures identify patients with more comorbid disease since treated isolated systolic hypertension improves outcomes even though diastolic pressures are in the \"enhanced risk\" range. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Isolated systolic hypertension'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Increased pulse pressure was associated with marked variations in risk of mortality, depending upon age, and the exact systolic and diastolic pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Framingham Heart Study also reported an increased incidence of poor outcomes as the blood pressure rises, even with values within the \"normal\" range. This study examined the risk of cardiovascular disease at 10 year follow-up among subjects with \"high-normal\" blood pressure at baseline examination, which was defined as a systolic blood pressure of 130 to 139 mmHg, a diastolic pressure of 85 to 89 mmHg, or both, and with \"normal\" blood pressure, which was defined as a systolic blood pressure of 120 to 129 mmHg, a diastolic pressure of 80 to 84 mmHg, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After adjustment for cardiovascular risk factors and when compared with optimal blood pressure (defined as systolic and diastolic blood pressures of less than 120 and 80 mmHg, respectively), the hazard ratios for a cardiovascular event at 10 years for those with high-normal values were 2.5 and 1.6 for women and men, respectively. Patients with \"normal\" blood pressure values also had an increased hazard ratio for a cardiovascular event compared with optimal blood pressure. Based in part upon this study, the seventh report of the Joint National Committee (JNC 7) added a new blood pressure category called prehypertension, which is defined as blood pressure of 120 to",
"    <span class=\"nowrap\">",
"     139/80",
"    </span>",
"    to 89 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a subsequent analysis of data from the Framingham Heart Study to determine the impact of prehypertension on specific cardiovascular events, it was demonstrated that prehypertension was associated with an increased risk of myocardial infarction (relative risk 3.5) and coronary artery disease (relative risk 1.7), but not stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to gender, other patient characteristics can influence the relationship between blood pressure and cardiovascular outcomes. In an analysis of data on 8960 participants aged 55 to 64 years in the Atherosclerosis Risk in Communities (ARIC) study, individuals with high normal (130 to",
"    <span class=\"nowrap\">",
"     139/85",
"    </span>",
"    to 89 mmHg) and normal (120 to",
"    <span class=\"nowrap\">",
"     129/80",
"    </span>",
"    to 85 mmHg) blood pressure had an increased risk of incident cardiovascular disease (RR 2.3 and 1.8, respectively) compared to optimal blood pressure",
"    <span class=\"nowrap\">",
"     (&lt;120/80",
"    </span>",
"    mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/11\">",
"     11",
"    </a>",
"    ]. The risk was substantially more pronounced among black, obese and diabetic individuals. Relative to optimal blood pressure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relative risk was 3.3 for high normal blood pressure among blacks.",
"     </li>",
"     <li>",
"      Relative risk was 4.1 for high normal blood pressure among diabetics.",
"     </li>",
"     <li>",
"      Relative risk was 3.6 for high normal blood pressure among individuals with a BMI &gt;30",
"      <span class=\"nowrap\">",
"       kg/m2.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk with increased blood pressure also appears to vary markedly from population to population. As an example, the relationship between blood pressure and mortality from coronary heart disease was evaluated in a 25 year follow-up study of over 12,000 men aged 40 to 59 years without heart disease who resided in seven different countries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/12\">",
"     12",
"    </a>",
"    ]. Over this period, nearly 1300 died from coronary heart disease. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among all populations, the relative increase in mortality from heart disease for a given increase in blood pressure was similar. When adjusted for individual variability, the relative risk of death was 1.28 for a 10 mmHg increase in systolic blood pressure.",
"     </li>",
"     <li>",
"      The risk of death in those with a blood pressure of",
"      <span class=\"nowrap\">",
"       140/85",
"      </span>",
"      mmHg was over three times higher among subjects from the United States and northern Europe compared to those from Japan and southern Europe (70 versus 20 deaths per 10,000 person-years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, the observation that there is a gradually increasing incidence of coronary disease and stroke and cardiovascular mortality with a rising the blood pressure does",
"    <strong>",
"     not",
"    </strong>",
"    prove a causal relationship. Rather, increasing blood pressure could be a marker for other risk factors such as increasing body weight, which is associated with dyslipidemia, glucose intolerance, and the metabolic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Decreased cardiovascular risk with therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best evidence for a causal role of increasing blood pressure in cardiovascular complications is an improvement in outcome with antihypertensive therapy. Treatment studies have demonstrated the efficacy of lowering both diastolic and systolic pressures in patients with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/2,3,13-15\">",
"     2,3,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood pressure control to achieve optimal cardiovascular outcomes includes achievement of goal blood pressure at the time of all or most measurements. This was best studied in a post hoc analysis from the INVEST trial which compared the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    in over 20,000 hypertensive patients with known coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/16\">",
"     16",
"    </a>",
"    ]. All patients, regardless of initial randomization, were divided into four groups according to the proportion of visits in which BP was in control: &lt;25, 25 to &lt;50, 50 to &lt;75, and &ge;75 percent. The risk of the primary outcome (death, nonfatal MI, and nonfatal stroke) decreased progressively and significantly from the group with the poorest control to the group with the best control during an average follow-up of 2.7 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H13#H13\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'INVEST trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lowering the blood pressure is also beneficial in some patients who have blood pressures near but not in the hypertensive range, primarily with concomitant conditions such as diabetes and chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Systolic and diastolic hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials of antihypertensive therapy demonstrated significant cardiovascular benefit in patients with systolic and diastolic hypertension that was most pronounced in severe and moderate disease. Although the number of patients was small in the severe and moderate hypertension trials, the magnitude of benefit was extremely high.",
"   </p>",
"   <p>",
"    The best data on the treatment of severe diastolic hypertension come from a trial in the 1960s of 143 men with diastolic pressures of 115 to 129 mmHg (average clinic blood pressure",
"    <span class=\"nowrap\">",
"     186/121",
"    </span>",
"    mmHg) who were randomly assigned to antihypertensive therapy or placebo, the incidence of cardiovascular events was 3 percent at 21 months in the treated group versus 39 percent at 16 months in the placebo group (p&lt;0.001) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/17\">",
"     17",
"    </a>",
"    ]. The shorter follow-up in the placebo group was due to the high number of terminating events. The average blood pressure during the trial was significantly lower in the treated group",
"    <span class=\"nowrap\">",
"     (143/91",
"    </span>",
"    mmHg versus no significant change in the placebo).",
"   </p>",
"   <p>",
"    The efficacy of treating moderate diastolic hypertension was demonstrated in a trial of 210 men with diastolic pressures of 105 to 114 mmHg who were randomly assigned to antihypertensive drugs or placebo. The incidence of cardiovascular events at three and a half years was significantly lower in the treated group (8 versus 32 percent; the difference in blood pressure between the groups was",
"    <span class=\"nowrap\">",
"     -31/-19",
"    </span>",
"    mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absolute benefit of blood-pressure lowering is much lower in patients with mild hypertension (90 to 104 mmHg). A summary of the results from 17 controlled trials of mild to moderate diastolic hypertension (almost all also had systolic hypertension) in adults under age 65 found that active treatment with antihypertensive medications led to a statistically significant 16 percent reduction in the number of coronary events and a 40 percent reduction in stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the aggregate, antihypertensive therapy of mild hypertension for four to five years prevented a coronary event in 0.7 percent of patients and a cerebrovascular event in 1.3 percent for a total benefit of approximately",
"    <strong>",
"     2 percent",
"    </strong>",
"    ; this included a reduction in cardiovascular mortality of 0.8 percent (",
"    <a class=\"graphic graphic_figure graphicRef52231 \" href=\"UTD.htm?43/29/44509\">",
"     figure 4",
"    </a>",
"    ). Thus, 100 patients must be treated for four to five years to prevent a complication in two.",
"   </p>",
"   <p>",
"    Two potential pitfalls must also be considered in evaluating these findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They may overestimate the benefit in mild hypertension, since patients with moderate hypertension (diastolic pressure as high as 115 mmHg in some studies) were also included.",
"     </li>",
"     <li>",
"      They may underestimate the total long-term benefit, since the studies were of relatively short duration and mild hypertension is a minor short-term risk. Thus, some have proposed an actuarial approach in which the benefits expected from the treatment of mild hypertension are estimated by comparison with insurance company actuarial data prior to the availability of antihypertensive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A report from the Framingham Heart Study confirmed the benefit of long-term antihypertensive therapy on cardiovascular disease incidence and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/21\">",
"     21",
"    </a>",
"    ]. All cause mortality and cardiovascular mortality over 10 years were significantly lower with antihypertensive therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In men, all cause mortality was reduced from 43 to 31 percent and cardiovascular mortality was reduced from 28 to 13 percent.",
"     </li>",
"     <li>",
"      In women, all cause mortality was reduced from 34 to 21 percent and cardiovascular mortality was reduced from 19 to 9 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even greater benefits have been shown with the treatment of elderly hypertensives (over age 65), most of whom have isolated systolic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/22\">",
"     22",
"    </a>",
"    ]. Because the elderly start at such higher overall cardiovascular risk, short term reductions in their hypertension provide apparently greater benefits than that observed in younger patients. However, among treated elderly patients with isolated systolic hypertension, there is a concern that the low diastolic pressure after therapy may interfere with tissue, particularly coronary, perfusion and possibly increase cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The related issue of goal blood pressure in hypertensive patients who are treated is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link&amp;anchor=H2#H2\">",
"     \"What is goal blood pressure in the treatment of hypertension?\", section on 'Systolic and diastolic hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2092868\">",
"    <span class=\"h4\">",
"     Low-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit from antihypertensive therapy is unproven in patients with mild hypertension who also have no preexisting cardiovascular disease. The meta-analysis described above suggested that, in patients with mild hypertension, antihypertensive therapy significantly reduced cardiovascular events by 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/19\">",
"     19",
"    </a>",
"    ]. However, some of the patients included in this meta-analysis had moderate rather than mild hypertension, and some had preexisting cardiovascular disease.",
"   </p>",
"   <p>",
"    A subsequent meta-analysis combined four placebo-controlled trials totalling 8912 patients with mild hypertension and no preexisting cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/23\">",
"     23",
"    </a>",
"    ]. During four to five years of follow-up, antihypertensive therapy produced lower rates of mortality (1.7 versus 2.0 percent) and stroke (0.3 versus 0.6 percent) but higher rates of myocardial infarction (2.0 versus 1.8 percent); none of these findings were statistically significant. The total number of events was small in this study, as would be expected among patients with mild hypertension and no cardiovascular disease. In addition, the four- to five-year follow-up was relatively short; a benefit from antihypertensive therapy among low-risk patients might require a substantially longer period of time to manifest. Finally, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     Felodipine",
"    </a>",
"    Event Reduction trial (FEVER) was not included in this meta-analysis, even though patients in the FEVER trial were similar to those enrolled in the trials that were included. As discussed elsewhere, the antihypertensive therapy in the FEVER trial significantly reduced mortality and cardiovascular events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link&amp;anchor=H6#H6\">",
"     \"What is goal blood pressure in the treatment of hypertension?\", section on 'Mild hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, low-risk patients with mild hypertension and no preexisting cardiovascular disease who fail to reduce their blood pressure with lifestyle modification should receive antihypertensive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Isolated systolic hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systolic pressure is the most important determinant of risk in hypertensive patients, particularly in patients over the age of 50 to 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/3\">",
"     3",
"    </a>",
"    ]. The value of treating isolated systolic hypertension has been demonstrated in multiple clinical trials. In the Systolic Hypertension in the Elderly Program (SHEP) trial, for example, it was estimated that approximately",
"    <strong>",
"     18",
"    </strong>",
"    patients had to be treated for five years to prevent a major cerebrovascular or cardiac event in one [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/24\">",
"     24",
"    </a>",
"    ]. However, these results",
"    <strong>",
"     underestimate",
"    </strong>",
"    the true benefit of effective therapy, since about 30 percent of treated patients did not reach goal blood pressure and 44 percent of patients in the placebo group ended up being treated at five years. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Isolated diastolic hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated diastolic hypertension (IDH) is defined as a diastolic pressure &ge;90 mmHg with a systolic pressure less than 140 mmHg. IDH is more common in younger men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/25,26\">",
"     25,26",
"    </a>",
"    ] who are overweight or obese [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/27\">",
"     27",
"    </a>",
"    ] and, in individuals under age 40, it is more common than systolic and diastolic hypertension (SDH) or isolated systolic hypertension (ISH) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/25\">",
"     25",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a 2001 report from the National Health and Nutrition Examination Survey (NHANES) III in the United States of untreated patients with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/25\">",
"     25",
"    </a>",
"    ]. IDH accounted for almost 60 percent of cases under age 40, approximately 35 percent between the ages of 40 and 49, and was rare in patients over age 60.",
"   </p>",
"   <p>",
"    In contrast to the demonstrated efficacy in the preceding sections of treating SDH and ISH, there are no randomized trials evaluating the efficacy of therapy in patients with IDH. Thus, decisions about antihypertensive therapy are based upon the natural history of IDH and the risk of cardiovascular complications.",
"   </p>",
"   <p>",
"    The natural history of untreated IDH was evaluated in a report from the Framingham Heart Study [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/26\">",
"     26",
"    </a>",
"    ]. Among 193 individuals with new onset IDH, 106 progressed to systolic and diastolic hypertension at a mean follow-up of 6.7 years (55 percent, adjusted hazard ratio 23 compared to optimal blood pressure",
"    <span class=\"nowrap\">",
"     [&lt;120/&lt;80",
"    </span>",
"    mmHg]).",
"   </p>",
"   <p>",
"    The risk of cardiovascular complications appears to be lower with IDH than with SDH and ISH [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/15,28-30\">",
"     15,28-30",
"    </a>",
"    ]. This could reflect one or both of the following: most patients are under age 40; and IDH may be associated with a lower cardiovascular risk. Furthermore, some [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/15,28,31\">",
"     15,28,31",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/30\">",
"     30",
"    </a>",
"    ] have suggested that IDH is not associated with an increase in risk compared to normotensive individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/15,28,31\">",
"     15,28,31",
"    </a>",
"    ]. A limitation to all of these studies is that it is not clear that the initial classification at baseline remained applicable during follow-up.",
"   </p>",
"   <p>",
"    The conflicting findings on prognosis of IDH can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No increase in all-cause mortality with IDH as defined above was noted at up to 32 years of follow-up in a prospective cohort study from Finland of 3267 initially healthy men 32 to 45 years of age who were not receiving antihypertensive drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/15\">",
"       15",
"      </a>",
"      ]. The patients with IDH also had a low rate of using antihypertensive drugs during follow-up.",
"     </li>",
"     <li>",
"      In contrast, a high rate of progression of IDH to systolic and diastolic hypertension (55 percent in 6.7 years) noted in the Framingham Heart Study [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/26\">",
"       26",
"      </a>",
"      ]. In addition, a 10-year follow-up Chinese study of over 26,500 subjects who were 35 years of age or older at baseline found that patients with IDH had, compared to normotensive patients, a significantly increased risk of stroke (relative risk 2.16 compared to 2.96 and 2.35 in patients with SDH and ISH, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no definitive data that address optimal therapy in patients with IDH. There is agreement among the authors and editors of this topic on the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The blood pressure as in all patients should be measured on at least three separate occasions to confirm the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=see_link\">",
"       \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonpharmacologic therapy is warranted, particularly salt restriction and weight loss in patients who are overweight which, as noted above, is common in IDH [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patient should be tested for evidence of end-organ damage, such as proteinuria and left ventricular hypertrophy on ECG, and for hypothyroidism, which has been associated with a rise in blood pressure more pronounced with diastolic compared to systolic pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with antihypertensive drugs is warranted in all patients with IDH who have evidence of end-organ damage. Most experts also suggest the use of antihypertensive drugs in patients without end-organ damage based upon the general recommendation in major society guidelines that the general goal blood pressure is",
"    <span class=\"nowrap\">",
"     &lt;140/&lt;90",
"    </span>",
"    mmHg, with lower values suggested in selected patients at increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with IDH should be able to attain goal blood pressure with a single drug. The choice of drug is discussed in detail elsewhere and depends in part upon whether there are specific indications for a particular class of drug (eg, beta blockers or nondihydropyridine calcium channel blockers for rate control in atrial fibrillation). Among patients without an indication for a particular class of drugs, younger patients such as those with IDH generally respond better to monotherapy with an ACE inhibitor or angiotensin II receptor blocker than a dihydropyridine calcium channel blocker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H14#H14\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Monotherapy based upon age and race'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Increased pulse pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that there is an enhanced risk for cardiovascular events associated with increases in the pulse pressure (defined as the systolic minus diastolic pressure). This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26823?source=see_link\">",
"     \"Increased pulse pressure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Goal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal blood pressure in all patients is less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg. Some groups of patients may benefit from a lower goal blood pressure. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using the above definitions from JNC 7, the following general approach can be used to determine which patients with hypertension require antihypertensive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/1,33,34\">",
"     1,33,34",
"    </a>",
"    ]. This approach largely includes the recommendations of JNC 7 for risk stratification and treatment and assumes accurate measurement of the blood pressure (",
"    <a class=\"graphic graphic_table graphicRef72683 \" href=\"UTD.htm?34/41/35484\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/1\">",
"     1",
"    </a>",
"    ]. The potential errors involved with this procedure are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=see_link\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients should undergo appropriate lifestyle (nonpharmacologic) modification (",
"    <a class=\"graphic graphic_table graphicRef62129 \" href=\"UTD.htm?42/24/43403\">",
"     table 1",
"    </a>",
"    ). In the absence of evidence for hypertensive target organ damage, the following decisions about antihypertensive medications are generally not made until there has been an adequate trial of nonpharmacologic therapy. However, if there is evidence for target organ damage, decisions on antihypertensive medications may be warranted earlier.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of end-organ damage, a patient should not be labeled as having hypertension unless the blood pressure is persistently elevated after",
"      <strong>",
"       three to six visits",
"      </strong>",
"      over a several month period. In one study, for example, there was a mean",
"      <span class=\"nowrap\">",
"       15/7",
"      </span>",
"      reduction in blood pressure in untreated patients between the first and third visits to a new physician [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/35\">",
"       35",
"      </a>",
"      ]. This difference has prognostic importance. The Medical Research Council Mild Hypertension Trial found a close correlation between cardiovascular risk and the systolic pressure measured three months after entry into the trial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/36\">",
"       36",
"      </a>",
"      ]. In contrast, a transient increase in systolic pressure at entry due to a white coat response was not associated with increased risk. During the initial evaluation period before a therapeutic decision is made, patients should also be encouraged to measure their blood pressure at home or work.",
"     </li>",
"     <li>",
"      Antihypertensive medications should generally be begun if the systolic pressure is",
"      <strong>",
"       persistently &ge;140 mmHg",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       the diastolic pressure is persistently &ge;90 mmHg",
"      </strong>",
"      in the office and at home, despite attempted nonpharmacologic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/1,33,34\">",
"       1,33,34",
"      </a>",
"      ]. Thus, systolic and diastolic hypertension, isolated systolic hypertension, and isolated diastolic hypertension all should be treated. Isolated diastolic hypertension is associated with increased cardiovascular risk [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/28,30\">",
"       28,30",
"      </a>",
"      ], but there are no treatment trials to prove benefit from antihypertensive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Starting with two drugs may be considered in patients with a baseline blood pressure more than",
"      <span class=\"nowrap\">",
"       20/10",
"      </span>",
"      mmHg above goal. This strategy may increase the likelihood that target blood pressures are achieved in a reasonable time period, but should be used cautiously in patients at increased risk for orthostatic hypotension (such as diabetics and the elderly). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In some patients with chronic kidney disease or known cardiovascular disease, antihypertensive therapy may be indicated when the systolic pressure is persistently above 130 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the diastolic pressure is above 80 mmHg (",
"      <a class=\"graphic graphic_table graphicRef72683 \" href=\"UTD.htm?34/41/35484\">",
"       table 2",
"      </a>",
"      ). The benefit of such blood pressure lowering in patients with chronic kidney disease is probably limited to patients excreting more than 0.5 to 1 g of protein per day. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"       \"What is goal blood pressure in the treatment of hypertension?\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with office hypertension, normal values at home, and no evidence of end-organ damage should undergo ambulatory blood pressure monitoring to see if they are truly hypertensive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link\">",
"       \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      On the other hand, 5 to 20 percent of patients with normal office readings have been found to have elevated out-of-the office readings by 24 hour automatic ambulatory blood pressure monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. These patients with \"masked\" hypertension appear to have an increased cardiovascular risk similar to those with elevated office and ambulatory readings [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a number of conditions (eg, heart failure, post-myocardial infarction), antihypertensive drugs are given to improve survival, independent of the blood pressure (",
"    <a class=\"graphic graphic_table graphicRef72683 \" href=\"UTD.htm?34/41/35484\">",
"     table 2",
"    </a>",
"    ). These uses are discussed separately in the appropriate topic reviews.",
"   </p>",
"   <p>",
"    The importance of other risk factors on both cardiovascular risk (",
"    <a class=\"graphic graphic_figure graphicRef55353 \" href=\"UTD.htm?24/31/25086\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/8,40\">",
"     8,40",
"    </a>",
"    ] and the likelihood of a beneficial response to antihypertensive therapy should not be underestimated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/4\">",
"     4",
"    </a>",
"    ]. In the MRC trial, for example, the number of patients with mild hypertension who had to be treated for five years to prevent one cardiovascular complication was",
"    <strong>",
"     262",
"    </strong>",
"    in the absence of any risk factors but only",
"    <strong>",
"     four",
"    </strong>",
"    in high-risk patients who smoked, were older than 55, and had a systolic pressure above 160 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Furthermore, cessation of smoking alone rapidly decreases coronary risk by approximately 35 to 40 percent, a benefit that is independent of the duration of smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3395?source=see_link\">",
"     \"Smoking and hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prehypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with prehypertension (systolic 120 to 139 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic 80 to 89 mmHg), but without diabetes, chronic kidney disease, or cardiovascular disease are treated with nonpharmacologic therapies such as weight reduction, sodium restriction, and avoidance of excess alcohol (",
"    <a class=\"graphic graphic_table graphicRef62129 \" href=\"UTD.htm?42/24/43403\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72683 \" href=\"UTD.htm?34/41/35484\">",
"     table 2",
"    </a>",
"    ). They should also have their blood pressure measured at least annually, or more frequently if home monitoring is available, since they are at significant risk of developing hypertension over time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44677?source=see_link\">",
"     \"Prehypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned above, individuals with prehypertension have an increased risk of cardiovascular events over time compared to those with normal blood pressure&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/9\">",
"     9",
"    </a>",
"    ]. However, there are as yet no data that lowering the blood pressure in this setting reduces cardiovascular risk, although antihypertensive therapy may delay overt hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4169/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"       \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"       \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=see_link\">",
"       \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/1\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/2\">",
"      Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/3\">",
"      Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/4\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/5\">",
"      Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/6\">",
"      Pastor-Barriuso R, Banegas JR, Dami&aacute;n J, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003; 139:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/7\">",
"      Sipahi I, Tuzcu EM, Schoenhagen P, et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006; 48:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/8\">",
"      Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/9\">",
"      Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/10\">",
"      Qureshi AI, Suri MF, Kirmani JF, et al. Is prehypertension a risk factor for cardiovascular diseases? Stroke 2005; 36:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/11\">",
"      Kshirsagar AV, Carpenter M, Bang H, et al. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006; 119:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/12\">",
"      van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000; 342:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/13\">",
"      Domanski M, Mitchell G, Pfeffer M, et al. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 2002; 287:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/14\">",
"      Benetos A, Thomas F, Bean K, et al. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med 2002; 162:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/15\">",
"      Strandberg TE, Salomaa VV, Vanhanen HT, et al. Isolated diastolic hypertension, pulse pressure, and mean arterial pressure as predictors of mortality during a follow-up of up to 32 years. J Hypertens 2002; 20:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/16\">",
"      Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/17\">",
"      Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/18\">",
"      Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/19\">",
"      Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/20\">",
"      Zanchetti A, Mancia G. Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. J Hypertens 1996; 14:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/21\">",
"      Sytkowski PA, D'Agostino RB, Belanger AJ, Kannel WB. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996; 93:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/22\">",
"      Wang JG, Staessen JA. Antihypertensive drug therapy in older patients. Curr Opin Nephrol Hypertens 2001; 10:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/23\">",
"      Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev 2012; 8:CD006742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/24\">",
"      Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/25\">",
"      Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001; 37:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/26\">",
"      Franklin SS, Pio JR, Wong ND, et al. Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study. Circulation 2005; 111:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/27\">",
"      Chirinos JA, Franklin SS, Townsend RR, Raij L. Body mass index and hypertension hemodynamic subtypes in the adult US population. Arch Intern Med 2009; 169:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/28\">",
"      Pickering TG. Isolated diastolic hypertension. J Clin Hypertens (Greenwich) 2003; 5:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/29\">",
"      Strandberg TE, Pitkala K. What is the most important component of blood pressure: systolic, diastolic or pulse pressure? Curr Opin Nephrol Hypertens 2003; 12:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/30\">",
"      Fang XH, Zhang XH, Yang QD, et al. Subtype hypertension and risk of stroke in middle-aged and older Chinese: a 10-year follow-up study. Stroke 2006; 37:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/31\">",
"      Hozawa A, Ohkubo T, Nagai K, et al. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home: the Ohasama study. Arch Intern Med 2000; 160:3301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/32\">",
"      Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/33\">",
"      Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/34\">",
"      Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/35\">",
"      Hartley RM, Velez R, Morris RW, et al. Confirming the diagnosis of mild hypertension. Br Med J (Clin Res Ed) 1983; 286:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/36\">",
"      Millar JA, Isles CG, Lever AF. Blood pressure, 'white-coat' pressor responses and cardiovascular risk in placebo-group patients of the MRC Mild Hypertension trial. J Hypertens 1995; 13:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/37\">",
"      Pickering TG. Effects of stress and behavioral interventions in hypertension: what is masked hypertension? J Clin Hypertens (Greenwich) 2003; 5:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/38\">",
"      Lurbe E, Torro I, Alvarez V, et al. Prevalence, persistence, and clinical significance of masked hypertension in youth. Hypertension 2005; 45:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/39\">",
"      Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of \"masked hypertension\" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/40\">",
"      Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1988; 296:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4169/abstract/41\">",
"      Kannel WB, Higgins M. Smoking and hypertension as predictors of cardiovascular risk in population studies. J Hypertens Suppl 1990; 8:S3.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3870 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4169=[""].join("\n");
var outline_f4_4_4169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WHAT LEVEL OF BP INCREASES RISK?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidemiologic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Decreased cardiovascular risk with therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Systolic and diastolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2092868\">",
"      Low-risk patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Isolated systolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Isolated diastolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Increased pulse pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Goal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prehypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3870\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3870|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/61/20447\" title=\"figure 1A\">",
"      CHD mortality related to BP and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/18/12591\" title=\"figure 1B\">",
"      Stroke mortality related to BP and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/31/25086\" title=\"figure 2\">",
"      Number of risk factors and CVD risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/46/17128\" title=\"figure 3A\">",
"      Mortality HTN under 65 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/23/33142\" title=\"figure 3B\">",
"      Mortality HTN over 65 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/29/44509\" title=\"figure 4\">",
"      Benefit of Rx of mild HTN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3870|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/24/43403\" title=\"table 1\">",
"      Lifestyle modifications in HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/41/35484\" title=\"table 2\">",
"      Classification and management of blood pressure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_4_4170="Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis";
var content_f4_4_4170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4170/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4170/contributors\">",
"     Mitchell H Rosner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4170/contributors\">",
"     Mark D Okusa, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4170/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4170/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/4/4170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/4/4170/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/4/4170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are hypotensive due to surgery, sepsis, bleeding, or other causes are at risk of developing postischemic (also called ischemic) acute tubular necrosis (ATN) especially if the impairment in renal perfusion is either severe or prolonged in duration. This disorder is characterized by a rising plasma creatinine concentration, a urine volume that may be reduced or normal, and a characteristic set of changes in the urinalysis, including many granular casts and a fractional excretion of sodium above 1 percent and fractional excretion of urea above 35 percent.",
"   </p>",
"   <p>",
"    The pathogenesis and etiology of postischemic ATN will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The diagnosis of ATN, potential therapies for postischemic ATN, and other causes of ATN are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=see_link\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process underlying ischemic ATN occurs in multiple phases, including prerenal (impairment in renal perfusion), initiation of injury, extension of injury, maintenance, and repair [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/3\">",
"     3",
"    </a>",
"    ]. The major histologic changes in ATN are effacement and loss of proximal tubule brush border, patchy loss of tubule cells, focal areas of proximal tubule dilatation, distal tubule casts, and areas of cellular regeneration that appear during the phase of recovery of renal function (",
"    <a class=\"graphic graphic_picture graphicRef72453 graphicRef51526 \" href=\"UTD.htm?31/39/32377\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the decline in renal function is usually more prominent than the severity of the histologic changes. In some cases necrotic cell death is not readily apparent and is restricted to the outer medullary regions (including the S3 segment of the proximal tubule and thick ascending limb of the loop of Henle). In addition to observable tubule obstruction and cell death, other factors may contribute to the decline in glomerular filtration rate (GFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tubules from multiple nephrons drain into a single collecting tubule. As a result, obstruction in a relatively small number of collecting tubules may lead to failure of filtration in a large number of nephrons.",
"     </li>",
"     <li>",
"      The combination of glomerular filtration and impaired proximal and loop reabsorptive function leads to increased sodium chloride delivery to the macula densa in individual nephrons. This activates the tubuloglomerular feedback mechanism causing afferent arteriolar constriction, which lowers the GFR in an attempt to reduce tubule flow rate [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=see_link&amp;anchor=H4#H4\">",
"       \"Chapter 2D: Regulation of GFR and renal plasma flow\", section on 'Tubuloglomerular feedback'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Back leak of filtered tubular fluid may occur across the damaged tubule epithelium [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Apoptosis occurs in both proximal and distal tubule cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peritubular capillaries in the outer medulla may be congested with leukocyte accumulation that impairs local renal blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of processes contribute to the pathogenesis of ATN, including endothelial and epithelial cell injury, intratubular obstruction, changes in local microvascular blood flow and immunological or inflammatory processes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endothelial and vascular components of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endothelium of the microcirculation of the kidney contributes to the pathogenesis of ATN. In human AKI following renal transplantation, there is a 40 to 50 percent decrease in renal blood flow but a substantially greater decrease in GFR that is not accounted for by the decrease in renal blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition regional blood flow is important in the pathogenesis of AKI. A disproportionate decrease in medullary blood flow relative to total renal blood flow results in medullary ischemia in AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypotension causes a reduction in renal blood flow in sepsis-induced AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/14\">",
"     14",
"    </a>",
"    ]. However some experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/15\">",
"     15",
"    </a>",
"    ] and human studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/16\">",
"     16",
"    </a>",
"    ] suggest an increase in renal blood flow, possibly related to changes in efferent arteriolar vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/17\">",
"     17",
"    </a>",
"    ]. Changes in microvascular blood flow may contribute to decreased tissue oxygenation in ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Sepsis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Endothelial cell injury causes disruption in microvascular blood flow, which is important in the initiation and extension phase of ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/3,19\">",
"     3,19",
"    </a>",
"    ]. A reduction in microvascular blood flow contributes to decreased renal perfusion, renal hypoxia, epithelial cell ischemia, and a resultant decrease in GFR. In particular, reductions in medullary blood flow may worsen the tubule damage caused by the initial ischemic insult. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Epithelial cell injury and dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Disruption of the endothelial cell layer may lead to impaired vascular reactivity, increased vascular permeability, and leukocyte recruitment and activation. Activation of the endothelium by ischemic injury leads to upregulation of adhesion molecules such as intracellular adhesion molecule 1 (ICAM-1) and P-selectin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/20\">",
"     20",
"    </a>",
"    ]. These adhesion molecules facilitate leukocyte-endothelial cell interactions such as macrophage recruitment and elaboration of chemokines [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/21\">",
"     21",
"    </a>",
"    ]. This recruitment of leukocytes serves as one of the early phases of inflammation after ischemia. The endothelial glycocalyx is a network of membrane-bound proteoglycans and glycoproteins that covers the endothelium and contributes to its normal function. Damage to the endothelium results in loss of the glycocalyx and disruption of the actin cytoskeleton [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dysfunction in the endothelial cell permeability barrier at the level of the peritubular capillaries probably contributes to the tubule backleak phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/3,23\">",
"     3,23",
"    </a>",
"    ]. Altered endothelial cell-cell contacts resulting in increased intracellular gap formation likely enhance microvascular permeability following ischemic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contributors to endothelial cell injury include the original ischemic insult, leukocyte-endothelial cell interactions, and other inflammatory mediators (such as tumor necrosis factor (TNF)). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Immunologic factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Endothelial injury leads to hemodynamic alterations that worsen the initial ischemic insult. There is a local imbalance of vasoactive factors that favors the release of the potent vasoconstrictor endothelin along with the reduced release of vasodilatory nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Altered coagulation and inflammation contribute to ischemic kidney injury. By inhibiting thrombin generation and activating protease activated receptor-1 (PAR-1), protein C may modulate endothelial dysfunction and protect against kidney injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombomodulin is an important factor in the anticoagulant protein C pathway and has anti-inflammatory properties. The administration of soluble thrombomodulin improved microvascular erythrocyte flow rates, reduced microvascular endothelial leukocyte rolling and attachment, minimized endothelial permeability and reduced renal injury in an ischemic kidney injury model [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epithelial cell injury and dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ischemic damage in ATN is generally most severe in the S3 segment of the proximal tubule and in the thick ascending limb of the loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/6,30\">",
"     6,30",
"    </a>",
"    ]. Early proximal tubule cells appear to be particularly susceptible to ischemia, while the renal medulla normally exists on the brink of hypoxia since the combination of low medullary blood flow and countercurrent exchange of oxygen lowers the pO2 to 10 to 20 mmHg. This sensitivity to hypoxia may be exacerbated by endogenously produced nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=see_link&amp;anchor=H6#H6\">",
"     \"Chapter 4A: Cell model for loop of Henle transport\", section on 'Passive Na+ reabsorption and medullary hypoxia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Poor oxygenation leads to a variety of secondary factors that promote the development of tubule injury, including the intracellular accumulation of calcium, the generation of reactive oxygen species, activation of phospholipases and proteases, depletion of ATP, and apoptosis (programmed cell death) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/32\">",
"     32",
"    </a>",
"    ]. The net effect may be either cell death or the sloughing of viable cells into the tubule lumen by impairment of normal cell-to-basement membrane adhesion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The latter process involves stress-induced redistribution of integrin receptors from the basolateral membrane, where adhesion to the matrix normally occurs, to the luminal membrane where luminal integral receptors promote attachment to other dislodged cells causing intratubular obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of other contributors to ischemic tubule injury or dysfunction have been explored in experimental models, but their contribution to human disease is undefined [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/35-40\">",
"     35-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemia-induced redistribution of membrane proteins &mdash; Ischemia disrupts the actin cytoskeleton that anchors the Na-K-ATPase pump to the basolateral membrane, allowing some of the pumps to redistribute onto the luminal membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. This interferes with normal ion transport by pumping sodium back into the tubule lumen. Recovery of function is associated with the return of Na-K-ATPase pumps to the basolateral membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/35\">",
"       35",
"      </a>",
"      ]. As mentioned above, beta-1 integrins are normally polarized to the basal cell membrane where they maintain cell-substratum adhesion. Ischemic injury results in the redistribution of integrins to the apical membrane with consequent shedding of tubule cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/41\">",
"       41",
"      </a>",
"      ]. The loss of epithelial polarity also leads to the loss of another basolateral membrane surface protein, the complement inhibitor, Crry, which permits activation of the alternative complement pathway resulting in the recruitment of macrophages and neutrophils [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mislocalized iron in the kidney &mdash; Neutrophil gelatinase-associated lipocalin (NGAL) is a kidney protein that induces renal cell differentiation and binds a siderophore that traps iron with high affinity. NGAL is induced in the kidney after ischemic injury, and the release of unbound iron that occurs as a consequence of ischemic injury can promote the formation of reactive oxygen species. The delivery of a lipocalin-siderophore-iron complex preserves renal histology in mice following ischemic injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clearance of apoptotic and necrotic cells &mdash; The natural course of acute kidney injury (AKI) is characterized by an initial phase of injury followed by a later phase of resolution. The clearance of apoptotic and necrotic cells is necessary to mitigate inflammation and initiate tissue repair. Although this role was thought to be exclusively due to macrophages, kidney injury molecule-1 (KIM-1 or TIM-1), an immunoglobulin superfamily cell-surface protein that is highly upregulated on the surface of injured kidney epithelial cells, has been shown to recognize apoptotic cell surface-specific phosphatidylserine epitopes and confer properties of endogenous phagocytes to kidney epithelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cellular receptors have been implicated in ischemia-reperfusion injury and recovery. Examples of such receptors include [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/39,45,46\">",
"       39,45,46",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Peroxisome proliferator-activated receptor (PPAR) &mdash; PPAR beta is a ligand-activated transcription factor that appears to protect against renal ischemia. PPAR beta is ubiquitously expressed in the nephron, particularly in the straight proximal tubule. Mice deficient in PPAR beta are much more susceptible to ischemia, and providing a PPAR beta ligand protects against ischemic renal injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/39\">",
"       39",
"      </a>",
"      ]. PPAR gamma agonists, such as fibrates, reduce inflammation and injury following",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      administration [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/47\">",
"       47",
"      </a>",
"      ]. PPAR gamma may have an antifibrotic action possibly mediated by hepatocyte growth factor [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Toll-like receptors &mdash; Toll-like receptors (TLRs) are pattern recognition receptors implicated in the immune response to pathogens. TLRs are expressed in both immune cells and renal epithelial cells and may serve as targets in the pathogenesis of ischemic injury. TLR 1, 2, 3, 4, and 6 are expressed in kidney epithelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/48-51\">",
"       48-51",
"      </a>",
"      ]. The expression of both TLR2 and TLR4 by tubular epithelial cells is increased following ischemia in mice, and the reduction of either TLR2 or 4 expression reduces the generation of ischemia-induced cytokines and preserves renal function following ischemic injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/46,52\">",
"       46,52",
"      </a>",
"      ]. Renal TLR2 RNA is expressed primarily in tubule cells and appears to be linked to the release of cytokines in response to ischemic injury. Mice that are deficient in TLR2 demonstrate a reduction in cytokine release and renal dysfunction compared with mice that express TLR2 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/46\">",
"       46",
"      </a>",
"      ]. The expression of TLR4 on both immune cells and renal parenchymal cells contributes to AKI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. The endogenous ligand for TLRs may be heat-shock proteins-60 and -70, mammalian DNA, RNA, interferon alpha, interferon beta, CD40-L, or high mobility group box protein 1(HMBG1), which are released by necrotic cells and ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/54-56\">",
"       54-56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      TLR9, an endosomal class of TLR, which is expressed in the spleen, may also contribute to the pathogenesis of AKI. TLR9 null mice and blockade of TLR9 with antisense oligonucleotides reduce mortality and severity of renal damage in a model of polymicrobial sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bradykinin receptors &mdash; Kinins, a set of hormones produced in the kidney, are vasodilators that may minimize renal ischemia. Support for this hypothesis is provided by the finding that mice without bradykinin B1 and B2 receptors are associated with marked",
"      <span class=\"nowrap\">",
"       ischemia/reperfusion",
"      </span>",
"      injury compared to wild-type mice [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Release of factors by necrotic or injured cells is likely important in the inflammatory responses that are critical to the extension and maintenance phases of AKI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/56\">",
"       56",
"      </a>",
"      ]. These factors include: high mobility group 1 protein [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/59\">",
"       59",
"      </a>",
"      ], heat shock proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/54\">",
"       54",
"      </a>",
"      ], and cytokines (IL-1, IL-6, TNF-alfa, IL-18) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/60-62\">",
"       60-62",
"      </a>",
"      ]. The chemokine receptor, CX3CR1, and its ligand, fractalkine, may play an early role in AKI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/21,63\">",
"       21,63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to ischemia, other factors may promote renal injury in selected settings:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Endotoxemia may play an important role in the multiple organ failure syndrome. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Etiology'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Cytokine release during hemodialysis with a bioincompatible membrane may delay renal recovery and increase mortality via cytokine activation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intratubular obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intratubular obstruction by cells and cellular debris is an important component of ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/64\">",
"     64",
"    </a>",
"    ]. Integrin receptors may contribute to this process, as adhesion of tubular epithelial cells to beta1-integrin ligands on the basement membrane may minimize tubule cell detachment and intratubular obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/65\">",
"     65",
"    </a>",
"    ]. The intraluminal casts are composed, in part, of Tamm-Horsfall protein, which is converted to a gel-like polymer in the setting of high local luminal sodium concentrations that is characteristic of ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different arms of the immune system appear to contribute to the pathogenesis of postischemic renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Postischemic renal injury is characterized by the appearance of neutrophils, natural killer T-cells and macrophages, both components of the innate immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/21,55,68\">",
"     21,55,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The innate immune system has evolved as a host defense mechanism that recognizes microbial products. Toll-like receptors and a limited number of other receptors expressed on dendritic cells and macrophages respond to highly conserved bacterial structures referred to as pathogen-associated molecular patterns (PAMPs), leading to an immediate and generic response. Pathogens are not the only agents that cause tissue damage. Tissue damage (eg, ischemia-reperfusion) is recognized at the cell level via receptor-mediated detection of intracellular proteins released by the dead cells. These proteins are referred to as \"alarmin\" and include endogenous molecules that signal tissue and cell damage such as mammalian DNA, heat shock proteins, high mobility group box 1 (HMBG-1). This model is referred to as the \"danger model\" [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Endogenous alarmins and exogenous PAMPs can be considered subgroups of damage-associated molecular patterns (DAMPs). Once activated, dendritic cells activate natural killer T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/69\">",
"     69",
"    </a>",
"    ]; an inflammatory and immune response leads to sequestration of leukocytes in inflamed sites, complement activation and eradication of pathogens through cytokines,",
"    <span class=\"nowrap\">",
"     complement/membrane",
"    </span>",
"    attack complex and natural killer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Complement activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement activation is an early event underlying ischemic injury and influences the recruitment of neutrophils and directly damages endothelium and surrounding cells. Observations in animal models and humans suggest that the activation of the alternative pathway that forms the membrane attack complex (C5-C9) may contribute to renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Several inhibitors of complement activation are present within the mouse kidney, although only complement receptor 1-related protein y (Crry) is present on mouse tubular epithelial cells. Reduced expression of Crry1 in the tubular epithelium increases sensitivity to ischemic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of the alternative complement pathway is also suggested by the demonstration of C3 deposition along the tubule basement membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/66\">",
"     66",
"    </a>",
"    ]. Upon activation, the complement system generates a number of inflammatory signals that lead to ongoing injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Adhesion molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1), may participate in the development of postischemic ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/72\">",
"     72",
"    </a>",
"    ]. The administration of anti-ICAM-1 antibodies preserves renal function and mitigates cell injury in experimental models of AKI, even if given as long as two hours after the ischemic insult. In addition, mutant mice without ICAM-1 are almost completely protected against ischemic renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/20\">",
"     20",
"    </a>",
"    ]. However, in human trials the administration of anti-ICAM-1 monoclonal antibody did not prevent ATN in deceased donor kidney transplant recipients following ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have also suggested a role for other adhesion molecules, such as E- and P-selectins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/74-77\">",
"     74-77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Immune cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing evidence suggests that inflammatory cells may play a role in ischemic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/11,68,78,79\">",
"     11,68,78,79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ICAM-1 may act, in part, by promoting neutrophil-endothelial cell interactions [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      T cells contribute to ischemia reperfusion injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/81\">",
"       81",
"      </a>",
"      ]. Mice deficient in effector CD4+ T cells are protected from ischemic injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/82,83\">",
"       82,83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The production of interferon gamma from natural killer T cells (a subpopulation of CD4+ cells) contributes to the pathogenesis of acute renal ischemia-reperfusion injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic deletion of CCR2 (the chemokine receptor for monocyte chemoattractant protein-1) is associated with decreased ischemic injury due, in part, to lower levels of macrophage activation and renal infiltration [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/21,85\">",
"       21,85",
"      </a>",
"      ]. Mice depleted of macrophages are protected from ischemic injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dendritic cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/87\">",
"       87",
"      </a>",
"      ] and natural killer cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/88\">",
"       88",
"      </a>",
"      ] contribute to ischemia-reperfusion injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Inflammatory mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of proinflammatory molecules are released in response to ischemic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/67,69,89\">",
"     67,69,89",
"    </a>",
"    ]. These include tumor necrosis factor-alpha, interleukin 6 and 8, chemokines, and bone morphogenetic protein-7. It is not known whether inhibition of such mediators ameliorates ischemic renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postischemic ATN is a common complication of severe ischemia (often due to prolonged hypotension), major surgery, or sepsis, particularly in combination with underlying comorbidities (such as chronic kidney disease, atherosclerosis, diabetes mellitus, advanced malignancy and poor nutrition) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative patients are at increased risk for ATN because preoperative intravascular volume depletion, anesthesia-induced hemodynamic changes, and intraoperative fluid losses can lead to reductions in renal blood flow, glomerular filtration rate (up to 30 to 45 percent), urine volume, and sodium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. Although most patients tolerate these changes well, some develop AKI that is most often due to ATN. The likelihood of tubule injury is increased if there is an additional insult, such as exposure to nephrotoxins (including medications, pigments [hemoglobin or myoglobin]) or repeated hypotensive episodes. Nearly two-thirds of patients who develop ATN have been exposed to more than one nephrotoxic insult.",
"   </p>",
"   <p>",
"    There are three surgical procedures that seem to confer the highest risk for ATN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal aortic aneurysm surgery, in which there may be periods of total renal ischemia if supra-aortic clamping is required [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/94,96\">",
"       94,96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surgery to correct obstructive jaundice, in which the postoperative reduction in glomerular filtration rate is roughly twice as great (60 versus 30 percent) as that seen with other forms of abdominal surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/97\">",
"       97",
"      </a>",
"      ]. This effect may be related to the absorption of endotoxin from the gut [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/98\">",
"       98",
"      </a>",
"      ]. In normal subjects, endotoxin absorption is limited by the detergent effect of bile salts on the lipopolysaccharide endotoxin molecule; this protection is lost with obstructive jaundice, since bile salt secretion is minimal. Preliminary experiments suggest that the administration of bile salts to such patients can prevent both the endotoxemia and the exaggerated renal vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac surgery, particularly coronary artery bypass graft (CABG) surgery with or without valve surgery. Important underlying risk factors include underlying renal insufficiency and myocardial dysfunction, combined CABG and valve surgery, and emergency surgery. Off-pump cardiac surgery appears to be associated with a lower risk for AKI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/99\">",
"       99",
"      </a>",
"      ]. Issues related to AKI after CABG are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H22#H22\">",
"       \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Acute kidney injury'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maintaining adequate systemic and renal hemodynamics during and after surgery, as well as limiting any nephrotoxin exposure, may diminish the risk of ATN in high-risk patients. Thus far, no specific pharmacological strategy has proven successful in preventing ATN. Strategies have targeted inflammatory pathways, oxidative stress, and renal hemodynamics without effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=see_link\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt or intermittent endotoxemia may play an important role in AKI that is observed as part of the multiple organ dysfunction syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/100\">",
"     100",
"    </a>",
"    ]. The likelihood of renal tubule injury with sepsis is increased if there are concurrent adverse clinical characteristics, including older age, underlying renal or liver insufficiency, and additional factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/101\">",
"     101",
"    </a>",
"    ]. Among the critically ill, sepsis is the most common cause of AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism by which endotoxemia leads to AKI is incompletely understood. Systemic hypotension, direct renal vasoconstriction, activation of vasoactive hormones (including renin-angiotensin-aldosterone system and endothelin), induction of nitric oxide synthase, release of cytokines (such as tumor necrosis factor, interleukin-1, interleukin-6, and chemokines), enhanced synthesis of reactive oxygen species, and activation of neutrophils by endotoxin and FMLP (a three amino acid [fMet-Leu-Phe] chemotactic peptide in the bacterial cell walls), all may contribute to renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/14,103-108\">",
"     14,103-108",
"    </a>",
"    ]. It has been shown, for example, that mild renal ischemia, which alone is not sufficient to cause renal injury, can lead to AKI in the presence of primed neutrophils as might occur with endotoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/109\">",
"     109",
"    </a>",
"    ]. The release of elastase and oxidants from neutrophils may also contribute to tubule damage in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/104,109\">",
"     104,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypotension is thought to cause a reduction in renal blood flow in sepsis induced AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/14\">",
"     14",
"    </a>",
"    ]. This concept has been challenged by experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/15\">",
"     15",
"    </a>",
"    ] and human studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/16\">",
"     16",
"    </a>",
"    ] that suggest an increase in renal blood flow, possibly related to changes in efferent arteriolar vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/17\">",
"     17",
"    </a>",
"    ]. Changes in microvascular blood flow may also contribute to decreased tissue oxygenation in ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to ATN, severe sepsis rarely leads to irreversible renal cortical necrosis. In this setting, endotoxin-induced endothelial injury may predispose to intrarenal thrombus formation by directly promoting platelet aggregation by diminishing the release of nitric oxide (endothelium-derived relaxing factor), which normally inhibits platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/110\">",
"     110",
"    </a>",
"    ], and by increasing the synthesis of plasminogen activator inhibitor type 1, leading to a reduction in fibrinolytic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postischemic ATN can also be seen in patients with severe hypovolemia or acute severe pancreatitis, in which multiple organ dysfunction is almost always present [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/112\">",
"     112",
"    </a>",
"    ]. In addition, even moderate degrees of volume depletion can increase the risk of renal failure in the presence of a nephrotoxin, such as an aminoglycoside antibiotic. In this setting, the impairment in cell energetics induced by the aminoglycoside increases the susceptibility to ischemic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/113\">",
"     113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other nephrotoxins, such as iodinated radiocontrast material, can also potentiate ischemic injury.",
"   </p>",
"   <p>",
"    Postischemic ATN may also occur in the absence of overt hypotension in conditions in which renal autoregulation is impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/114\">",
"     114",
"    </a>",
"    ]. This is most commonly observed in patients with chronic kidney disease, liver failure, and longstanding hypertension. The concomitant use of drugs such as angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or nonsteroidal anti-inflammatory drugs can potentiate renal injury by further impairing autoregulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROTECTIVE EFFECT OF HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;ATN appears to be an unusual complication of heart failure even at similar degrees of systemic hypotension as seen with volume depletion or sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/115\">",
"     115",
"    </a>",
"    ]. In animal models, for example, cell energy stores (such as ATP) are better preserved in cardiogenic shock than in hemorrhagic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which this occurs is not clear, but increased left heart filling pressures in heart failure lead to reduced renal sympathetic tone via a cardiorenal reflex and enhanced release of atrial natriuretic peptide, both of which may contribute to the maintenance of renal blood flow and the GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?4/4/4170/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. Thus, as renal perfusion falls in heart failure, patients tend to maintain a prerenal picture (high",
"    <span class=\"nowrap\">",
"     BUN/creatinine",
"    </span>",
"    ratio, low urine sodium concentration) without progression to ATN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The underlying process of ischemic ATN occurs in multiple steps, including prerenal, initiation, extension, maintenance, and repair. This results in a variety of major histologic changes in ATN, including the effacement and loss of proximal tubule brush border, patchy loss of tubule cells, focal areas of proximal tubule dilatation, distal tubule casts and areas of cellular regeneration that appear during the phase of recovery of renal function. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of processes contribute to the pathogenesis of tubular necrosis. These include endothelial and epithelial cell injury, intratubular obstruction, and immunologic or inflammatory processes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ATN is a common complication of severe ischemia (often due to prolonged hypotension), major surgery, or sepsis. ATN frequently occurs in combination with underlying comorbidities. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For unclear reasons, ATN appears to be an unusual complication of heart failure even at degrees of systemic hypotension that are associated with ATN in other circumstances. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Protective effect of heart failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/1\">",
"      Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011; 121:4210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/2\">",
"      Eltzschig HK, Eckle T. Ischemia and reperfusion--from mechanism to translation. Nat Med 2011; 17:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/3\">",
"      Molitoris BA, Sutton TA. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int 2004; 66:496.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD. Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987. pp. 84-104.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/5\">",
"      Solez K, Morel-Maroger L, Sraer JD. The morphology of \"acute tubular necrosis\" in man: analysis of 57 renal biopsies and a comparison with the glycerol model. Medicine (Baltimore) 1979; 58:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/6\">",
"      Myers BD, Moran SM. Hemodynamically mediated acute renal failure. N Engl J Med 1986; 314:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/7\">",
"      Mason J, Takabatake T, Olbricht C, Thurau K. The early phase of experimental acute renal failure. III. Tubologlomerular feedback. Pflugers Arch 1978; 373:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/8\">",
"      Myers BD, Hilberman M, Spencer RJ, Jamison RL. Glomerular and tubular function in non-oliguric acute renal failure. Am J Med 1982; 72:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/9\">",
"      Donohoe JF, Venkatachalam MA, Bernard DB, Levinsky NG. Tubular leakage and obstruction after renal ischemia: structural-functional correlations. Kidney Int 1978; 13:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/10\">",
"      Lieberthal W, Koh JS, Levine JS. Necrosis and apoptosis in acute renal failure. Semin Nephrol 1998; 18:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/11\">",
"      Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004; 66:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/12\">",
"      Alejandro V, Scandling JD Jr, Sibley RK, et al. Mechanisms of filtration failure during postischemic injury of the human kidney. A study of the reperfused renal allograft. J Clin Invest 1995; 95:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/13\">",
"      Karlberg L, Norl&eacute;n BJ, Ojteg G, Wolgast M. Impaired medullary circulation in postischemic acute renal failure. Acta Physiol Scand 1983; 118:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/14\">",
"      Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 351:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/15\">",
"      Langenberg C, Wan L, Egi M, et al. Renal blood flow in experimental septic acute renal failure. Kidney Int 2006; 69:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/16\">",
"      Brenner M, Schaer GL, Mallory DL, et al. Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter. Chest 1990; 98:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/17\">",
"      Wan L, Langenberg C, Bellomo R, May CN. Angiotensin II in experimental hyperdynamic sepsis. Crit Care 2009; 13:R190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/18\">",
"      De Backer D, Creteur J, Preiser JC, et al. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002; 166:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/19\">",
"      Sheridan AM, Bonventre JV. Cell biology and molecular mechanisms of injury in ischemic acute renal failure. Curr Opin Nephrol Hypertens 2000; 9:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/20\">",
"      Kelly, KJ, Williams, WW Jr, Colvin, RB, et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996; 97:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/21\">",
"      Li L, Huang L, Sung SS, et al. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int 2008; 74:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/22\">",
"      Rubio-Gayosso I, Platts SH, Duling BR. Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2006; 290:H2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/23\">",
"      Brodsky SV, Yamamoto T, Tada T, et al. Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am J Physiol Renal Physiol 2002; 282:F1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/24\">",
"      H&ouml;rbelt M, Lee SY, Mang HE, et al. Acute and chronic microvascular alterations in a mouse model of ischemic acute kidney injury. Am J Physiol Renal Physiol 2007; 293:F688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/25\">",
"      Kohan DE. Endothelins in the kidney: physiology and pathophysiology. Am J Kidney Dis 1993; 22:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/26\">",
"      Schwartz D, Blantz RC. Nitric oxide, sepsis, and the kidney. Semin Nephrol 1999; 19:272.",
"     </a>",
"    </li>",
"    <li>",
"     Gupta, A, Williams, MD, Macias, WL, et al. Activated protein C and acute kidney injury: Selective targeting of PAR-1. Curr Drug Targets. Dec 1 2009 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/28\">",
"      Joyce DE, Gelbert L, Ciaccia A, et al. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276:11199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/29\">",
"      Sharfuddin AA, Sandoval RM, Berg DT, et al. Soluble thrombomodulin protects ischemic kidneys. J Am Soc Nephrol 2009; 20:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/30\">",
"      Brezis M, Rosen S, Silva P, Epstein FH. Renal ischemia: a new perspective. Kidney Int 1984; 26:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/31\">",
"      Koivisto A, Pittner J, Froelich M, Persson AE. Oxygen-dependent inhibition of respiration in isolated renal tubules by nitric oxide. Kidney Int 1999; 55:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/32\">",
"      Kaushal GP, Basnakian AG, Shah SV. Apoptotic pathways in ischemic acute renal failure. Kidney Int 2004; 66:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/33\">",
"      Noiri E, Gailit J, Sheth D, et al. Cyclic RGD peptides ameliorate ischemic acute renal failure in rats. Kidney Int 1994; 46:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/34\">",
"      Noiri E, Romanov V, Forest T, et al. Pathophysiology of renal tubular obstruction: therapeutic role of synthetic RGD peptides in acute renal failure. Kidney Int 1995; 48:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/35\">",
"      Molitoris BA, Dahl R, Geerdes A. Cytoskeleton disruption and apical redistribution of proximal tubule Na(+)-K(+)-ATPase during ischemia. Am J Physiol 1992; 263:F488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/36\">",
"      Fish EM, Molitoris BA. Alterations in epithelial polarity and the pathogenesis of disease states. N Engl J Med 1994; 330:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/37\">",
"      Alejandro VS, Nelson WJ, Huie P, et al. Postischemic injury, delayed function and Na+/K(+)-ATPase distribution in the transplanted kidney. Kidney Int 1995; 48:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/38\">",
"      Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005; 115:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/39\">",
"      Letavernier E, Perez J, Joye E, et al. Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol 2005; 16:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/40\">",
"      Molitoris BA, Dagher PC, Sandoval RM, et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009; 20:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/41\">",
"      Gailit J, Colflesh D, Rabiner I, et al. Redistribution and dysfunction of integrins in cultured renal epithelial cells exposed to oxidative stress. Am J Physiol 1993; 264:F149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/42\">",
"      Thurman JM, Ljubanovi�� D, Royer PA, et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 2006; 116:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/43\">",
"      Thurman JM, Lenderink AM, Royer PA, et al. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol 2007; 178:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/44\">",
"      Ichimura T, Asseldonk EJ, Humphreys BD, et al. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 2008; 118:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/45\">",
"      Li Y, Wen X, Spataro BC, et al. hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 2006; 17:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/46\">",
"      Leemans JC, Stokman G, Claessen N, et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005; 115:2894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/47\">",
"      Li S, Gokden N, Okusa MD, et al. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005; 289:F469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/48\">",
"      Wolfs TG, Buurman WA, van Schadewijk A, et al. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol 2002; 168:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/49\">",
"      Tsuboi N, Yoshikai Y, Matsuo S, et al. Roles of toll-like receptors in C-C chemokine production by renal tubular epithelial cells. J Immunol 2002; 169:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/50\">",
"      Anders HJ, Banas B, Schl&ouml;ndorff D. Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 2004; 15:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/51\">",
"      El-Achkar TM, Huang X, Plotkin Z, et al. Sepsis induces changes in the expression and distribution of Toll-like receptor 4 in the rat kidney. Am J Physiol Renal Physiol 2006; 290:F1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/52\">",
"      Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117:2847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/53\">",
"      Cunningham PN, Wang Y, Guo R, et al. Role of Toll-like receptor 4 in endotoxin-induced acute renal failure. J Immunol 2004; 172:2629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/54\">",
"      Kim BS, Lim SW, Li C, et al. Ischemia-reperfusion injury activates innate immunity in rat kidneys. Transplantation 2005; 79:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/55\">",
"      Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/56\">",
"      Rosin DL, Okusa MD. Dangers within: DAMP responses to damage and cell death in kidney disease. J Am Soc Nephrol 2011; 22:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/57\">",
"      Yasuda H, Leelahavanichkul A, Tsunoda S, et al. Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol 2008; 294:F1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/58\">",
"      Kakoki M, McGarrah RW, Kim HS, Smithies O. Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 2007; 104:7576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/59\">",
"      Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192:565.",
"     </a>",
"    </li>",
"    <li>",
"     Thuman JM. Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol 2006 [In press].",
"    </li>",
"    <li>",
"     Wu, H, Craft, ML, Wang, P, et al. IL-18 Contributes to Renal Damage after Ischemia-Reperfusion. J Am Soc Nephrol 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/62\">",
"      He Z, Lu L, Altmann C, et al. Interleukin-18 binding protein transgenic mice are protected against ischemic acute kidney injury. Am J Physiol Renal Physiol 2008; 295:F1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/63\">",
"      Oh DJ, Dursun B, He Z, et al. Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol 2008; 294:F264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/64\">",
"      OLIVER J, MacDOWELL M, TRACY A. The pathogenesis of acute renal failure associated with traumatic and toxic injury; renal ischemia, nephrotoxic damage and the ischemic episode. J Clin Invest 1951; 30:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/65\">",
"      Molina A, Ubeda M, Escribese MM, et al. Renal ischemia/reperfusion injury: functional tissue preservation by anti-activated {beta}1 integrin therapy. J Am Soc Nephrol 2005; 16:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/66\">",
"      Wangsiripaisan A, Gengaro PE, Edelstein CL, Schrier RW. Role of polymeric Tamm-Horsfall protein in cast formation: oligosaccharide and tubular fluid ions. Kidney Int 2001; 59:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/67\">",
"      Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004; 66:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/68\">",
"      Li L, Okusa MD. Blocking the immune response in ischemic acute kidney injury: the role of adenosine 2A agonists. Nat Clin Pract Nephrol 2006; 2:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/69\">",
"      Li L, Huang L, Vergis AL, et al. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest 2010; 120:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/70\">",
"      Zhou W, Farrar CA, Abe K, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/71\">",
"      Thurman JM, Lucia MS, Ljubanovic D, Holers VM. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int 2005; 67:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/72\">",
"      Molitoris BA, Marrs J. The role of cell adhesion molecules in ischemic acute renal failure. Am J Med 1999; 106:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/73\">",
"      Salmela K, Wramner L, Ekberg H, et al. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation 1999; 67:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/74\">",
"      Singbartl K, Green SA, Ley K. Blocking P-selectin protects from ischemia/reperfusion-induced acute renal failure. FASEB J 2000; 14:48.",
"     </a>",
"    </li>",
"    <li>",
"     Singbartl, K, Forlow, SB, Ley, K. Platelet, but not endothelial, P-selectin is critical for neutrophil- mediated acute postischemic renal failure. FASEB J 2001 Nov; 15:2337.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/76\">",
"      Burne MJ, Rabb H. Pathophysiological contributions of fucosyltransferases in renal ischemia reperfusion injury. J Immunol 2002; 169:2648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/77\">",
"      Nemoto T, Burne MJ, Daniels F, et al. Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int 2001; 60:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/78\">",
"      Day YJ, Huang L, McDuffie MJ, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 2003; 112:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/79\">",
"      Lai LW, Yong KC, Igarashi S, Lien YH. A sphingosine-1-phosphate type 1 receptor agonist inhibits the early T-cell transient following renal ischemia-reperfusion injury. Kidney Int 2007; 71:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/80\">",
"      Caramelo C, Alvarez Arroyo MV. Polymorphonuclear neutrophils in acute renal failure: new insights. Nephrol Dial Transplant 1998; 13:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/81\">",
"      Ascon M, Ascon DB, Liu M, et al. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney Int 2009; 75:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/82\">",
"      Burne MJ, Daniels F, El Ghandour A, et al. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 2001; 108:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/83\">",
"      Day YJ, Huang L, Ye H, et al. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol 2006; 176:3108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/84\">",
"      Li L, Huang L, Sung SS, et al. NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury. J Immunol 2007; 178:5899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/85\">",
"      Furuichi K, Wada T, Iwata Y, et al. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol 2003; 14:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/86\">",
"      Day YJ, Huang L, Ye H, et al. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am J Physiol Renal Physiol 2005; 288:F722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/87\">",
"      Li L, Okusa MD. Macrophages, dendritic cells, and kidney ischemia-reperfusion injury. Semin Nephrol 2010; 30:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/88\">",
"      Zheng X, Zhang X, Feng B, et al. Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol 2008; 173:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/89\">",
"      Menke J, Iwata Y, Rabacal WA, et al. CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. J Clin Invest 2009; 119:2330.",
"     </a>",
"    </li>",
"    <li>",
"     Jo, SK, Rosner, MH, Okusa, MD. Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon. Clinical JASN 2007 doi: 10.2215/CJN.03280906. [In press].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/91\">",
"      Sesso R, Roque A, Vicioso B, Stella S. Prognosis of ARF in hospitalized elderly patients. Am J Kidney Dis 2004; 44:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/92\">",
"      Chawla LS, Abell L, Mazhari R, et al. Identifying critically ill patients at high risk for developing acute renal failure: a pilot study. Kidney Int 2005; 68:2274.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD. Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987, pp. 87-88.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/94\">",
"      Myers BD, Miller DC, Mehigan JT, et al. Nature of the renal injury following total renal ischemia in man. J Clin Invest 1984; 73:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/95\">",
"      Esson ML, Schrier RW. Diagnosis and treatment of acute tubular necrosis. Ann Intern Med 2002; 137:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/96\">",
"      Gornick CC Jr, Kjellstrand CM. Acute renal failure complicating aortic aneurysm surgery. Nephron 1983; 35:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/97\">",
"      DAWSON JL. POST-OPERATIVE RENAL FUNCTION IN OBSTRUCTIVE JAUNDICE: EFFECT OF A MANNITOL DIURESIS. Br Med J 1965; 1:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/98\">",
"      Cahill CJ. Prevention of postoperative renal failure in patients with obstructive jaundice--the role of bile salts. Br J Surg 1983; 70:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/99\">",
"      Nigwekar SU, Kandula P, Hix JK, Thakar CV. Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized and observational studies. Am J Kidney Dis 2009; 54:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/100\">",
"      Wardle EN. Acute renal failure and multiorgan failure. Nephron 1994; 66:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/101\">",
"      Yegenaga I, Hoste E, Van Biesen W, et al. Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. Am J Kidney Dis 2004; 43:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/102\">",
"      Bagshaw SM, Uchino S, Bellomo R, et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007; 2:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/103\">",
"      Badr KF, Kelley VE, Rennke HG, Brenner BM. Roles for thromboxane A2 and leukotrienes in endotoxin-induced acute renal failure. Kidney Int 1986; 30:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/104\">",
"      Linas SL, Whittenburg D, Repine JE. Role of neutrophil derived oxidants and elastase in lipopolysaccharide-mediated renal injury. Kidney Int 1991; 39:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/105\">",
"      Khan RZ, Badr KF. Endotoxin and renal function: perspectives to the understanding of septic acute renal failure and toxic shock. Nephrol Dial Transplant 1999; 14:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/106\">",
"      Boffa JJ, Just A, Coffman TM, Arendshorst WJ. Thromboxane receptor mediates renal vasoconstriction and contributes to acute renal failure in endotoxemic mice. J Am Soc Nephrol 2004; 15:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/107\">",
"      Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/108\">",
"      Boffa JJ, Arendshorst WJ. Maintenance of renal vascular reactivity contributes to acute renal failure during endotoxemic shock. J Am Soc Nephrol 2005; 16:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/109\">",
"      Linas SL, Whittenburg D, Parsons PE, Repine JE. Mild renal ischemia activates primed neutrophils to cause acute renal failure. Kidney Int 1992; 42:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/110\">",
"      Shultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest 1992; 90:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/111\">",
"      Keeton M, Eguchi Y, Sawdey M, et al. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol 1993; 142:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/112\">",
"      Tran DD, Oe PL, de Fijter CW, et al. Acute renal failure in patients with acute pancreatitis: prevalence, risk factors, and outcome. Nephrol Dial Transplant 1993; 8:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/113\">",
"      Zager RA. Gentamicin effects on renal ischemia/reperfusion injury. Circ Res 1992; 70:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/114\">",
"      Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med 2007; 357:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/115\">",
"      Schrier RW. Nephrology forum: acute renal failure. Kidney Int 1979; 15:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/116\">",
"      Zager RA. Adenine nucleotide changes in kidney, liver, and small intestine during different forms of ischemic injury. Circ Res 1991; 68:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/4/4170/abstract/117\">",
"      Thames MD, Abboud FM. Reflex inhibition of renal sympathetic nerve activity during myocardial ischemia mediated by left ventricular receptors with vagal afferents in dogs. J Clin Invest 1979; 63:395.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7228 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4170=[""].join("\n");
var outline_f4_4_4170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endothelial and vascular components of injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epithelial cell injury and dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intratubular obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunologic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Complement activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Adhesion molecules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Immune cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Inflammatory mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROTECTIVE EFFECT OF HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7228\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7228|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/24/44419\" title=\"picture 1A\">",
"      Light microscopy of acute tubular necrosis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/58/19366\" title=\"picture 1B\">",
"      Light microscopy of acute tubular necrosis II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=related_link\">",
"      Chapter 2D: Regulation of GFR and renal plasma flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=related_link\">",
"      Chapter 4A: Cell model for loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_4_4171="Complex sleep apnea contributors";
var content_f4_4_4171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F84027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F84027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features associated with, or contributing to, appearance of central apneas in complex sleep apnea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Non-rapid eye movement (REM) sleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe OSA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supine position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Higher CPAP levels (\"over-titration\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Higher pressure support level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Altitude",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral breathing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opioid narcotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congestive heart failure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4171=[""].join("\n");
var outline_f4_4_4171=null;
var title_f4_4_4172="Cerebral palsy rate by pleurality";
var content_f4_4_4172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cerebral palsy rate in Western Australia by pleurality, 1980-1989",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"6\" width=\"13%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Singleton",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Twin",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Triplet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\">",
"        Standardized",
"       </td>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\">",
"        Standardized",
"       </td>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\">",
"        Standardized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Per 1000 live births",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        1.60",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        7.40",
"       </td>",
"       <td class=\"centered\">",
"        4.6",
"       </td>",
"       <td class=\"centered\">",
"        26.67",
"       </td>",
"       <td class=\"centered\">",
"        16.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Per 1000 1st-year survivors",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        1.60",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        7.32",
"       </td>",
"       <td class=\"centered\">",
"        4.6",
"       </td>",
"       <td class=\"centered\">",
"        27.91",
"       </td>",
"       <td class=\"centered\">",
"        17.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Per 1000 pregnancies",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        1.59",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        13.24",
"       </td>",
"       <td class=\"centered\">",
"        8.3",
"       </td>",
"       <td class=\"centered\">",
"        75.95",
"       </td>",
"       <td class=\"centered\">",
"        47",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Oleszczuk JJ, Oleszczuk AK, Keith DM, Keith LG. Twin and triplet birth: facts, figures, and costs. Female Patient 2003; 28:11. Copyright &copy; 2003 Jaroslaw J Oleszczuk, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4172=[""].join("\n");
var outline_f4_4_4172=null;
var title_f4_4_4173="Hepatic adenoma symptoms";
var content_f4_4_4173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relative frequency of presentation of hepatic adenoma in female patients with a history of contraceptive steroid use from 4 clinical studies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 252px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mean frequency and range are shown. In many patients, there was more than one presenting symptom.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Zimmerman H. Hormonal derivatives and related drugs. In: Hepatoxicity: The Adverse effects of drugs and other chemicals on the liver, 2nd edition, Zimmerman H (Ed), Lippincott Williams and Wilkins, Philadelphia 1999. p.555.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4173=[""].join("\n");
var outline_f4_4_4173=null;
var title_f4_4_4174="Contents: Oncologic disease";
var content_f4_4_4174=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/6/44141\">",
"       Geriatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Oncologic disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Oncologic disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/0/34826\">",
"           Adjuvant systemic therapy for older women with early stage breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/51/11066\">",
"           Adjuvant therapy for resected colon cancer in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/47/20217\">",
"           Clinical presentation, diagnosis, and staging of bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/56/41864\">",
"           Comprehensive geriatric assessment for patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/6/37992\">",
"           Endometrial carcinoma: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/27/18874\">",
"           Endometrial carcinoma: Epidemiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/43/15029\">",
"           Management of malignant gliomas in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/60/25540\">",
"           Meningioma: Clinical presentation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/54/20328\">",
"           Meningioma: Epidemiology, risk factors, and pathology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/44/2759\">",
"           Overview of the management of urothelial (transitional cell) bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/55/24441\">",
"           Prostate cancer in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/42/10922\">",
"           Systemic chemotherapy for cancer in elderly persons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/38/36455\">",
"           Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/2/4133\">",
"           Systemic treatment of recurrent meningioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/31/41466\">",
"           Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/36/44616\">",
"           Treatment of benign (WHO grade I) meningioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/60/40903\">",
"           Treatment of metastatic breast cancer in older women",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-EF64FEAF79-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f4_4_4174=[""].join("\n");
var outline_f4_4_4174=null;
var title_f4_4_4175="Plain versus time released";
var content_f4_4_4175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plain nictonic acid has a greater effect on lipoprotein concentrations than timed-release nicotinic acid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 305px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low doses of plain (crystalline) nicotinic acid have more favorable effects than most timed-release forms on serum triglyceride and high-density lipoprotein (HDL) cholesterol concentrations. The plain and timed-release forms have similar effects at any given dose on serum low-density lipoprotein (LDL) cholesterol concentrations. The majority of the effects on serum triglyceride and HLD cholesterol concentrations occur with lower doses of nicotinic acid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Knopp, RH, N Engl J Med 1999; 341:498.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_4_4175=[""].join("\n");
var outline_f4_4_4175=null;
